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Prokaryotic PLA2 from Streptomyces violaceoruber, shows an unusual 
property to be secreted into the culture medium, instead of its retention in the 
bacterial periplasmic space when overexpressed in E. coli using the pelB 
periplasmic signal. Moreover, this molecule is structurally the least complex 
and one of the smallest among PLA2 enzymes. Hence, in my doctoral study I 
have attempted to engineer PLA2 to (a) develop an extracellular expression 
system; and (b) design a mini PLA2 scaffold.  
The secretory nature of prokaryotic PLA2 was exploited by using it as a tag to 
express other disulphide rich proteins in the extracellular medium, as it would 
provide an oxidative environment for folding. Using this system, we 
successfully expressed fusion protein PLA2-Krait natriuretic peptide (one 
disulphide) and PLA2-Denmotoxin (a three-finger toxin with five disulphides) 
in the culture medium.  After cleavage, correctly folded, functionally-active 
Krait natriuretic peptide was obtained. Although PLA2-Denmotoxin was 
expressed as soluble fusion with all the cysteines oxidized, it resisted protease 
cleavage, probably due to stearic hindrance, which could be overcome by 
providing optimal linker size for protease access (current ongoing work). 
Thus, we demonstrated the utility of prokaryotic PLA2 in the expression of 
complex proteins. 
The prokaryotic PLA2 has a unique three dimensional structure. Although it 
possess the conserved three-helix catalytic core seen in other secretory PLA2s 
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it has a two-helix domain located away from its catalytic core, which seems to 
have no direct role in catalysis. With just two disulphide bonds and this 
structural uniqueness, this enzyme provided us a model to attempt the design 
of minimal PLA2 scaffolds and study its structure and activity. To achieve this, 
two generations of mutants were created. The first generation of mutants 
(ΔHelix-1, ΔHelix-1, 2) evaluated the requirement of the first two helices in 
the PLA2 activity. Both mutants did not show any enzymatic activity although 
they were folded with wild-type like disulphide linkages. The second 
generation of mutant was designed to stabilize the interactions on the exposed 
hydrophobic surface (F66Q and Y71Q) of ΔHelix-1, 2. Despite the 
replacement with polar residues, the minimal scaffold lacked PLA2 activity 
suggesting the necessity to study the three dimensional structure of the 
minimized mutants and re-design existing mutants to stabilize the molecule 
further. Hence from this study we were able to use the PLA2 as an expression 
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1 CHAPTER ONE: Introduction 
1.1 Protein engineering 
Protein engineering is an area of protein science, first described by scientist 
Kevin M. Ulmer in 1983 with the paper titled ‘Protein Engineering’ (Ulmer, 
1983). At that time, protein engineering was performed with basic techniques 
like mutagenesis mostly to enhance the properties of commercially useful 
products like enzymes. Since then, till the time of compiling this thesis, a lot 
of advancements have taken place in the field of protein design and 
engineering. It is a broad area comprising of a several tools and techniques to 
design proteins with improved or new function. Although it is an interesting 
area, it is equally challenging, partly due to our lack of complete 
understanding of protein folding and the complex nature of proteins (Dill and 
MacCallum, 2012). The field of protein design and engineering has two broad 
approaches, rational design and de-novo design. 
 
1.1.1 Rational protein design 
In the rational approach, proteins are designed and engineered from a known 
starting molecule whose structure and properties are well studied. Although 
the final aim is to gain or enhance a desired function, the alterations in the 
molecule are based on the known information of its structure, fold and 
2 
 
mechanism (Berry and Lu, 2011). This strategy includes redesign of existing 
proteins with or without combinatorial approaches. 
 
1.1.2 De-novo protein design  
In the de-novo approach, entirely new proteins are designed from the scratch 
only with the idea of the final desired function. This approach relies heavily on 
computer algorithms to obtain the final predicted design. This strategy is 
gradually improving with time with the availability of numerous three 
dimensional structures of proteins in the databases and advancements in 
programming and computational power (Huang et al., 2011; Khatib et al., 
2011). 
Proteins are engineered either for our understanding of its structure-function 
relationship or dissection of action mechanism. Proteins are also engineered 
for improving its function for commercial benefits (Tsigos et al., 2001; Van 
den Burg et al., 1998). The proteins which are engineered are mostly 
antibodies or enzymes. While antibodies are engineered to enhance its affinity 
towards antigens (Holliger and Hudson, 2005; Presta, 2005; Reiter et al., 
1996), enzymes are mostly engineered to improve its catalytic properties 




1.2 Enzyme engineering  
Enzymes are very efficient biological catalyst. For a long time enzymes were 
the prime targets for protein engineering primarily for its industrial and 
commercial importance (Arnold et al., 2015). Nevertheless enzymes are 
engineered for understanding its catalytic mechanism. Recent development in 
de-novo enzyme design has led to a few successes in development of enzymes 
with completely new catalytic function (Nanda and Koder, 2010; 
Rothlisberger et al., 2008; Siegel et al., 2010). Further some of these enzymes 
were later improved by additional remodeling and combinatorial techniques 
(Eiben et al., 2012). Therefore today enzyme engineering is accomplished by 
rational approach, combinatorial techniques or de-novo design. 
 
1.3 Phospholipases  
Phospholipases are a widespread group of enzymes possessing the ability to 
cleave various bonds in phospholipids (Figure 1.1). They play diverse roles 
from defence in snake to signal transduction, production of lipid mediators and 
digestion in humans (Aloulou et al., 2012). Based on the specific bond they 




Figure 1.1 Different phospholipases and the bond they cleave 
Four different phospholipases, named after the specific bonds on the lipid 
molecule it cleaves. 
 
1.4 Phospholipase A2 
Phospholipase A2 (EC 3.1.1.4) stereospecifically hydrolyze the sn-2 
carboxylic ester bond of phospholipids (Figure 1.1). This group of enzyme is 
very interesting because of its unusual property to perform catalysis in the 
interface between protein and organized lipids (Scott and Sigler, 1994). 
Moreover the synthesis of arachidonic acid as a result of phospholipid 
catalysis plays a key role in the prostaglandin production including other 
inflammatory mediators (Ricciotti and FitzGerald, 2011). An exclusive kinetic 
property of secretory phospholipase A2 (sPLA2) is their preference for 
organized substrates such as monolayers, membranes, vesicles or micelles 
(Scott and Sigler, 1994). This is evident form the fact that sPLA2s show 
PLA1, sn-1 carboxylic ester 
PLA2, sn-2 carboxylic ester 
PLC, phosphoric ester PLD, phosphoric ester 
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enhanced activity (up to three orders of magnitude greater) on lipid aggregates 
than dispersed substrates. sPLA2s are calcium dependent enzymes. Although 
calcium is weakly bound (Kd greater than 10
-4
 M), it is necessary for catalysis 
(Scott and Sigler, 1994). This group of enzymes has been thoroughly 
investigated due to its availability in milligram quantities from sources such as 
pancreas and reptile venoms, before the advent of heterologous protein 
expression systems.  
 
1.4.1 Classification  
The superfamily of PLA2 enzymes can be classified into 15 groups (including 
subgroups), which includes five types of distinct enzymes, namely secretory 
phospholipase A2 (sPLA2), cytosolic phospholipase A2 (cPLA2), calcium 
independent phospholipase A2 (iPLA2), platelet-activating factor acetyl 
hydrolases (PAF-AH) and lysosomal PLA2s (Schaloske and Dennis, 2006). 
This classification is based on the group numbering system updated in the year 
2006, although a number of new PLA2 have been discovered till date as a 
result of substantial investigations in this field. Group 1 and 2 comprises of 
secretory enzymes from old world and new world snake venoms respectively. 
The group 3 comprises of bee venom PLA2 and the group 14 comprises the 




1.4.2 Catalysis  
PLA2s are unique in the fact that they are highly water soluble enzymes 
capable of hydrolyzing water insoluble substrates, i.e, phospholipids (Kini, 
2003). They possess the ability to hydrolyze lipids in monomeric, micellar or 
bilayer forms, with an increase in catalytic activity up to 10,000 folds at the 
critical micellar concentration (CMC) of the phospholipids (Verger and De 
Haas, 1973). This is due to interfacial activation, a phenomenon common 
among PLA2s. This unusual property is aided by an interfacial recognition site, 
which is independent of the catalytic site. PLA2s also exhibit distinct 
phospholipid head group preferences. Bilayer vesicles are hydrolyzed in two 
distinct modes. In hopping mode of catalysis, binding to the bilayer and 
desorption occurs during each catalytic turnover cycles. In scooting mode of 
catalysis, the enzyme remains bound to the interface between the catalytic 
turnover cycles (Kini, 2003). These distinct modes of catalysis have been 
characterized by different experimental conditions (Jain and Berg, 1989). 
 
1.4.3 Pharmacological effects 
Reptilian venom PLA2s exhibits a variety of pharmacological effects such as 
neurotoxicity, myotoxicity, cardiotoxicity, anticoagulant effects, hemolytic 
effects and edema inducing activity to mention a few (Kini, 2003). The 
pharmacological effects exhibited by the snake PLA2s are mostly independent 
of other components with a few exceptions. For a few PLA2s the full potential 
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of pharmacological activity is seen only when in complex with other proteins. 
In case of β-bungarotoxin the components are held together by covalent bonds 
whereas in case of crotoxin, the components are associated with each other by 
non-covalent interactions. 
 
1.5 Structural homology in PLA2s 
Secretory PLA2s are highly homologous containing between 119 to 143 amino 
acid residues. This homology is based on mostly their tertiary structure 
displaying a large proportion of invariant residues. Conserved residues directly 
participate in catalysis or occupy structurally sensitive positions in the enzyme 
structure (Scott and Sigler, 1994). The number of cysteine residues range from 
4 to 14 and are involved in disuphide bonds, stabilizing the tertiary structure. 
The following are the conserved substructures seen in secretory PLA2s 
 
1.5.1 Three-helix catalytic core 
All secretory PLA2s possesses the conserved three helix catalytic core. This 
core contains the active site residues which are conserved in secretory PLA2s. 
Although the tertiary structure might contain loops and β-strands holding the 
three-helix core in place, the three helix bundle is conserved in all secretory 




1.5.2 Active site geometry 
The catalytic triad in the active site of secretory PLA2s is made of histidine, 
aspartic acid and a water molecule. Because it is a calcium dependent enzyme, 
the position of calcium in the tertiary structure is crucial for the catalysis. In 
the active site of all secretory PLA2s the geometry of active site histidine, 
aspartic acid and calcium is conserved. The distance between histidine and 
aspartic acid is around 2.9 Å whereas the distance between histidine and 
calcium is around 6.3 Å (Figure 1.2 b).  
 
Figure 1.2 Structural similarity in phospholipase A2 
A. Cobra venom PLA2  B. Prokaryotic PLA2  C. Bee venom PLA2. Active site 
histidine, aspartic acid and calcium are shown in red.  
D, E and F. Same PLA2 structures as above, with active site zoomed in. 
Although the three well studied molecules belong to three different class of 
phospholipases, they share the same three dimensional topology containing the 
three helix catalytic core. 
The distances between the active site histidine, aspartic acid and calcium is 





H 64 D 85 H 34 D 64 
D F E 









1.5.3 Calcium binding loop 
All secretory PLA2s have a loop which contains the residues that co-ordinate 
the calcium ion. Oxygen atoms form the backbone carbonyls, carboxylate of 
aspartate and solvent water co-ordinate the calcium with a co-ordination 
number of 7 forming a pentagonal bipyramidal co-ordination cage. This 
calcium binding loop also  forms the superior wall of the substrate-binding 
pocket (Scott and Sigler, 1994). 
 
1.5.4 Antiparallel helices 
Secretory PLA2s show another common substructure, the antiparallel helices. 
Two helices among the three in the catalytic core are linked together by 
disulphide bridges to form a stable structure holding several important 
residues involved in catalysis. Side chains arising from these helices aid in 
coordination of calcium ion. It also forms the deeper regions of the 
hydrophobic channel (Scott and Sigler, 1994). 
 
1.6 Prokaryotic phospholipase A2 
The prokaryotic phospholipase A2 is the first secretory PLA2 identified from a 
soil bacterium, Streptomyces violaceoruber (Sugiyama et al., 2002). This 
enzyme has been characterized both functionally and structurally. Structural 
investigations of this new class of secretory PLA2 have yielded both the NMR 
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solution and x-ray crystal structures in calcium free and bound form (Matoba 
et al., 2002; Sugiyama et al., 2002). From the NMR and x-ray data, interesting 
insights regarding this new class of molecule was elucidated. It was the first 
secretory PLA2 with relatively simple structure containing only two disulphide 
linkages. Unlike other well studied secretory PLA2s which contains both α-
helices and β-strands, this enzyme contains only α-helices in its tertiary 
structure. It was one of the the smallest secretory PLA2 described with only 
122 amino acid residues and a molecular weight of 13.5 kDa (Figure 1.3 a, b).  
 
Figure 1.3 Crystal structure of prokaryotic PLA2 (1FAZ) 
A. Side view  B. Top view. Three green helices form the core of the enzyme. 
Relevant structures are coloured.  
Dark blue, catalytic residues; red, residues involved in calcium co-ordination; 
light blue, disulfide bonds. Helices 1 (black) and 2 (grey) appear to be away 










1.7 Unique properties of prokaryotic PLA2 
The prokaryotic PLA2 is the first secretory PLA2 identified from soil bacteria. 
This enzyme possesses a few unique and interesting characteristics which are 
exploited in the studies described in this thesis. 
 
1.7.1 Unique structural features of prokaryotic PLA2 
The structure elucidated from the NMR and crystal data, shows the presence 
of only two disulphide bonds compared to the other well studied secretory 
PLA2s which have 10-14 disulphides. Therefore this bacterial PLA2 is the only 
one with the simplest structure among all known secretory PLA2s. Figure 1.4 
shows the disulphides in red circles. Moreover it has only five α-helices, 
compared to other well studied secretory PLA2s, which are composed of both 
α-helices and β-strands in their tertiary structure. More interestingly, the 
molecule seems to be comprised of two domains with N-terminal 2-helix 
bundle and C-terminal 3-helix bundle. The C-terminal 3-helix core is the 
catalytic core of the molecule containing the conserved residues needed for 
catalysis. The N-terminal 2-helix bundle seems be located away from the C-
terminal catalytic domain, hence predicted to not to take part in catalysis 
Figure 1.4, red square box). This secretory PLA2 is one of the smallest in size 




Figure 1.4 Unique structural features of prokaryotic PLA2 
The two disulphide bonds shown in red circles. 
The N-terminal 2-helix bundle is shown in red rectangle. 
 
These structural features make this molecule one of the smallest and simplest 
secretory PLA2. This provided us with a model to minimize the size of the 
enzyme to develop a small PLA2 scaffold, by retaining the catalytic domain 
and its enzymatic activity. This forms one part of my thesis to design smaller 






1.7.2 Unique expression properties of prokaryotic PLA2 
The prokaryotic PLA2 when expressed with pelB signal sequence using the 
pET 22b vector system was shown to be expressed in the extracellular medium 
instead of its retention in the periplasmic space (Takemori et al., 2012). 
Although the plasmid construct was designed for periplasmic expression of 
PLA2, most of the activity was seen in the culture medium when compared to 
the cytosol (Takemori et al., 2012). The comparison between this unusual 
extracellular expression of PLA2 using the pelB signal and the usual 




Figure 1.5 Periplasmic expression compared to extracellular expression 
A and B. The common periplasmic expression, where the protein is signaled to 
the bacterial periplasm where it is retained.  
Top: pET22b plasmid showing pelB signal and  protein-X.  
Bottom: Schematic representation of a E. coli cell showing retention of 
proteins in the bacterial periplasm. 
B. Extracellular expression seen in case of pelB-PLA2, where the  expressed 
protein is secreted into the culture medium. 
Top: pET22b plasmid showing pelB signal and  pkPLA2.  
Bottom: Schematic representation of a E. coli cell showing secretion of 
pkPLA2 from the bacterial periplasm to extracellular medium. 
 
 
The yield of purified prokaryotic PLA2 obtained from this system of 
extracellular expression was reported to by 20 mg/l culture supernatant 
(Takemori et al., 2012). Although the mechanism of this extracellular export 























unclear, this phenomenon is independent of the catalytic activity of PLA2 
(Takemori et al., 2012). 
The prokaryotic PLA2, although containing two disulphides was able to 
express in considerably large quantities, fold and function like the authentic 
enzyme, led us to hypothesize that the prokaryotic PLA2 could be used as a 
carrier to express other disulphide rich proteins of interest in the extracellular 
medium. This forms the first part of my thesis, to test this system of 
extracellular expression using the prokaryotic PLA2 as an expression tag. 
 
1.8 Structural minimization of Proteins 
Mini proteins or protein domains are considered to be the smallest functional 
unit of a protein. Protein minimization, a type of protein engineering endeavor, 
helps us understand the first principles of protein folding, structure-function 
relationship and design of stable scaffolds. 
 
1.8.1 Importance of mini proteins 
Although proteins are complex molecules with distinct folds and functions, the 
determinants leading to their signature folds and thus functions are not very 
clear. Even though a lot of investigations are done in this direction, our ability 
to design any molecule with a defined function, just from its primary sequence 
is limited by our understanding of protein folding. Functional proteins with 
16 
 
minimal structure provide us excellent models for studying protein folding.  
Smaller motifs also offer simple and traceable models for understanding 
determinants of protein stability, structure and function (Braisted and Wells, 
1996). Moreover smaller proteins are more amenable to synthetic chemistry, 
making it easier for further design and engineering. 
Mini proteins serve as stable scaffolds which can be used as a starting template 
for the design of other useful molecules. Desired function can be imparted into 
small scaffolds by grafting of active sites (Stricher et al., 2006). Small stable 
scaffolds with a desired biological activity can be used for the design of other 
modular biologics or biotechnological tools.  
 
1.8.2 Strategies for minimization 
The minimization strategy usually start from rational design of minimal 
domains, followed by combinatorial and evolution methods to gain or enhance 
its function followed by further minimization and so on, until the desired 
structure and function is attained. Grafting of active sites into a structurally 





1.8.3 Mini protein design endeavors 
Protein engineering is a challenging area which navigates between chance and 
reason (Baker, 2011; Corey and Corey, 1996). Not a lot of protein/enzyme 
minimization efforts have been successful. Protein A domain was minimized 
from 59 residues to 33 residues (Braisted and Wells, 1996), ANP was 
minimized from 28 residues to 15 residues (Li et al., 1995). Scorpion toxin 
scaffold, with 37 amino acid residues was used as a natural scaffold to impart 
zinc binding activity (Vita et al., 1995). 
 
1.9 Importance of recombinant protein expression 
Recombinant protein expression has been one of the key technologies in the 
advancement of our understanding of numerous biological processes. As the 
increasing research and commercial applications require large quantities of 
high quality proteins, the strategies for efficient production of recombinant 
proteins are gaining importance (Terpe, 2006).  
 
1.9.1 Recombinant protein expression systems 
Till date, there are several well standardized systems for overexpressing 
proteins (Assenberg et al., 2013). Although there are various limitations in 
each of these systems, the expression systems for use in each target protein 
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needs to be chosen based on properties of the target protein. The following are 
some of the most common systems for recombinant protein expression: 
 
1.9.2 Bacterial systems 
Prokaryotic systems including Gram negative and Gram positive bacteria are 
utilized for production of recombinant proteins (de Vos et al., 1997; Vrancken 
et al., 2010). Although both Gram positive and Gram negative bacteria have 
been able to express recombinant proteins, the Gram negative bacteria E. coli 
is the system of choice for various reasons.  
E. coli was the first Gram negative bacterium utilized for recombinant 
pharmaceutical protein production (Assenberg et al., 2013). Till date large 
amount of information have been gained about its manipulation and usage 
(Baneyx, 1999; Prazeres et al., 1999). It can be grown to very high cell 
densities with simple defined media requirements (Ozturk, 1996). A very high 
level of expression is possible using commercially available pET vector 
systems. Despite all these advantages, there are several other drawbacks such 
as inability to correctly fold complex and disulphide rich proteins due to 
reducing environment of the cytoplasm.  Formation of posttranslational 
modifications including glycosylation and acylation is not possible, which 
might be desirable in some proteins of interest. 
On the other hand, Gram positive bacteria have been used for recombinant 
protein expression with the advantage of production of large amounts of 
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folded proteins and low amounts pyrogens (Harwood, 1992). The production 
of protease subtilisin by B. subtilis, is an example of its usage. Although Gram 
positive bacteria are capable of producing recombinant proteins, the yields are 
lower compared to the Gram negative counterparts. Moreover, the 
recombinant plasmids are not stable hence chromosomal integration of the 
gene of interest is the only route to obtain stable recombinant cells. 
 
1.9.3 Yeast systems 
The yeast expression system includes the species S. cerevisiae and P. pastoris, 
which are commonly used. The first manipulated yeast species for 
recombinant expression was S. cerevisiae (Kjeldsen, 2000). Although 
recombinantly expressed proteins using S. cerevisiae sytem can secrete folded 
proteins to the extracellular media, the effects of extracellular proteases and 
post translational modification limits its use. 
Methylotrophic yeasts, such as P. pastoris are hosts with high potential 
(Gellissen, 2000). It was a host proposed for recombinant protein expression 
as early as in the 1980s (Cereghino and Cregg, 2000). P. pastoris has been 
reported to grow up to very high cell densities (100 g/l dry biomass) with  
protein yield up to 1 g/l (Cereghino and Cregg, 2000). Although it has 
advantages, handling yeast is more troublesome than bacteria. The growth rate 
being slow (culturing requires 4 to 6 days), makes this a comparatively less 
efficient expression method. Moreover transformation and selection of stable 
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integrants of gene in yeast system is more laborious compared to 
transformation of  plasmid in bacterial system. 
 
1.9.4 Mammalian system 
The mammalian system for recombinant protein production is the most 
sophisticated system available. The ability of mammalian cells to fold and 
perform complex posttranslational modifications in the expressed protein is 
unmatched by any other system. Moreover this system has been optimized for 
culture up to 10,000 l scale. But there are several hurdles in expression of 
proteins using this system. Factors like expression yield, time required for 
gene manipulation, time required for protein production, prone to 
contamination and expenses in bioreactor and culture conditions, make this 
system less reliable for most protein production endeavors.  
 
1.9.5 Tags for bacterial expression systems 
Although there are sophisticated systems to express recombinant proteins, the 
bacterial system is the most robust due to its ease of handling, fast growth, 
easy genetic manipulation and high levels of expression. Therefore many 
strategies have been developed to get the most out of bacterial expression 
system, despite its limitations. For aiding the production of soluble proteins 
and purification, tags have been developed for the purpose of either increasing 




1.9.5.1 Histidine tag (6x His)  
This is the simplest tag consisting of six tandem repeats of histidine, devised 
for purification of protein expressed in the bacterial cytoplasm. It was 
designed for affinity purification of tagged proteins by immobilized metal 
affinity chromatography (IMAC) (Choe et al., 2002). It has the most versatile 
use in bacterial expression system. But this tag has only chelation property and 
do not contribute to the enhancement of solubility of the target proteins. It can 
be used with both soluble and denatured inclusion body proteins. 
 
1.9.5.2 Thioredoxin (Trx) tag  
Thioredoxin is a moderate size (~12 kDa) expression tag which is usually used 
for enhancing solubility of the target protein. The thioredoxin molecule used is 
from bacterial source. The high solubility of Trx is evident from the fact that, 
when it is expressed from plasmid vectors in E. coli, it accumulates up to 40% 
of the total cellular proteins, while remaining completely soluble (Lunn et al., 
1984). The fold of thioredoxin is very compact with 90% of primary sequence 
involved in prominent elements of secondary structure. In the tertiary 
structure, Trx is exposed to the surface both at the N and C-terminus of the 
molecule, allowing it to be linked at any terminus (Katti et al., 1990). 
Thiredoxin is proposed to serve as covalently linked chaperone protein, by 
holding the folding intermediates of the heterologous protein in soluble form 
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long enough, until it attains its final confirmation (LaVallie et al., 1993). 
Moreover Trx tag when fused to 6x His tag, can be used for both enhancing 
solubility and assisting in affinity purification.  
 
1.9.5.3 Glutathione S-transferase (GST) tag 
Glutathione S-transferase (GST) is a 26 kDa naturally occurring protein form 
eukaryotic cells. This protein was identified from the parasitic helminth 
Schistosoma japonicum, which was later used in the design of expression tag 
in the pGEX vector system (Harper and Speicher, 2011; Smith and Johnson, 
1988). GST is used as a fusion partner in expression systems because it 
exhibits chaperone like properties, aiding in folding proteins (Harper and 
Speicher, 2011). It serves both as a solubilization and an affinity tag. The 
fusion can be affinity purified by the use of immobilized glutathione resin and 
eluted by use of reduced glutathione.  
 
1.9.5.4 Maltose binding protein (MBP) tag 
Maltose binding protein (MBP) is a ~40 kDa expression tag which serves dual 
purpose of solubilization and affinity purification of heterologous proteins 
expressed in E. coli. This protein was originally developed as a tag by NEB in 




protein-expression). The fusion can be bound by amylose resin and eluted with 
maltose. 
 
1.9.5.5 Expression with pelB signal (export tag) 
pelB leader sequence is a sequence of 22 amino acid residues, which when 
attached to any protein, exports it to the bacterial periplasm. pelB specifically 
refers to pectate lyase B of Erwinia carotovora. The gene sequence of this 
signal must be attached to the gene of interest to transport the translated 
sequence to the periplasm, where the signal is processed leading to the 
accumulation of the target protein. The transport from cytoplasm to periplasm 
is mediated mostly by the Sec-pathway or the Tat pathway. In Sec dependent 
pathway, SecB (cytosolic chaperone) or the ribonucleoprotein SRP (signal 
recognition particle) binds to the unfolded preprotein harboring the N-terminal 
signal and transports then to inner membrane bound SecA (Yoon et al., 2010). 
Proteins entering the bacterial periplasmic space are exposed to a relatively 
oxidizing environment, hence aids in the formation of disulphide bonds in 
structurally complex proteins. 
 
1.9.6 pET vector system for bacterial expression 
The most powerful system developed till date for the cloning and expression 
of recombinant proteins in E. coli is the pET system. pET vector system is 
derived from the pBR322 plasmid and modified to take the advantage of the 
24 
 
T7 bacteriophage gene 10. This promotes high-level transcription and 
translation by the encoded RNA pol that is highly specific for the T7 promoter 
sequences, rarely found in genomes other than T7 phage. Target genes are 
silent in the uninduced state, preventing expression (important if genes 
expressed are toxic for the cell) and upon induction, the target gene will only 
be transcribed by highly active polymerase. The T7 RNA pol is so active and 
selective that, when fully induced, most of the cell’s resources are diverted to 
target gene expression, such that the target product could constitute more than 
50% of cell’s proteins in a few hours of induction (Novagen pET manual, 10th 
edition).  
 
Figure 1.6 Control elements of the pET system 








1.10 Aim and scope of the study 
Prokaryotic PLA2 from Streptomyces violaceoruber, shows an unusual 
property to be secreted into the culture medium, instead of its retention in the 
bacterial periplasmic space when overexpressed in E. coli using the pelB 
periplasmic signal. The PLA2 secreted to the medium was shown to be 
completely active and a total yield of 20 mg/l culture supernatant. The PLA2 
having two disulphides was efficiently folded with a considerably good yield, 
gave us an idea to use its potential to export other complex disulphide rich 
proteins of interest to the extracellular medium. Moreover, this molecule is 
structurally the least complex with two disulphide bonds and one of the 
smallest among PLA2 enzymes. Having a unique structure with its catalytic 
core separated from the N-terminal 2-helix bundle, provided us a model to 
design a mini PLA2 scaffold. 
In this thesis we wanted to exploit the two interesting and unique features of 
the prokaryotic phospholipase A2 to  
 
1. Design an extracellular expression system 
 Using the full length prokaryotic PLA2 as a tag for expression of 
disulphide rich proteins in the extracellular medium 
 Study of minimal region of prokaryotic PLA2 for necessary for export 




2. Design a mini PLA2 scaffold 
 Design, expression and refolding of 1st generation mutants (∆ Helix 1 
and ∆ Helix 1 & 2) 
 Structural and functional assessment of the 1st generation mutants 
 Design, expression and refolding of 2nd generation mutants (∆ Helix 1 
& 2- F66Q-Y71Q) 































CHAPTER  TWO 



















2 CHAPTER TWO: Prokaryotic PLA2 as a tag for 
extracellular expression 
2.1 Introduction 
Recombinant protein expression has been one of the key technologies in the 
advancement of our understanding of numerous biological processes. As the 
increasing research and commercial applications require large quantities of 
high quality proteins, the strategies for efficient production of recombinant 
proteins are gaining importance (Terpe, 2006).  
Until date, although there are several well standardized systems for 
overexpressing proteins there are various limitations in each of these systems 
pertaining to soluble protein production and correct folding of disulphide rich 
proteins. 
The prokaryotic PLA2 exhibits a unique property of being secreted into the 
culture medium when expressed with pelB periplasmic signal (Takemori et al., 
2012). Therefore we wanted to exploit this unusual property of the prokaryotic 
PLA2 to design an extracellular expression system.  
Structurally complex proteins containing multiple disulphides are difficult to 
express in correctly folded, soluble form using bacterial expression systems. 
The reducing environment of bacterial cytoplasm does not provide the optimal 
condition for disulphide bond formation, hence leads to protein misfolding and 
inclusion body formation. Although refolding proteins from the inclusion body 
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is the only way to produce structurally complex disulphide rich proteins in 
reasonable quantities, the method and the steps involved are often painstaking 
(Cabrita and Bottomley, 2004). Moreover, the refolding conditions need to be 
developed strategically and often empirically to get a considerable yield of the 
final refolded protein. 
The prokaryotic PLA2 which is secreted into the extracellular medium, first 
enters the periplasmic space (with relatively more oxidizing environment 
compared to cytoplasm) where the signal is processed, following which it exits 
the periplasm into the culture medium. This type of expression pathway not 
only provides the disulphide rich proteins a suitable environment to fold 
correctly, but also eases the downstream purification strategies. Additionally, 
being an enzyme, the extent of extracellular expression could be readily 
evaluated from the total activity in the culture medium using any simple assay 
technique. 
With the ease of handling and robustness of bacterial system combined with 
advantages of folding disulphide rich proteins (usually seen in expression 
system involving higher organisms), this system could provide us a valuable 
tool to express other complex proteins. 
In this chapter we look into a few aspects of the prokaryotic PLA2 to design an 
extracellular expression system. Primarily we have used the molecule as an 
expression tag to express other target proteins in the culture medium. 
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Furthermore, we have also tried to study the minimal region for export and 

















2.2 Materials and Methods 
2.2.1 Materials: 
Materials used in the experiments were obtained from the following sources:  
 
Codon optimized synthetic DNA of prokaryotic PLA2 was cloned in pUC-57 
from Genscript corporation (Piscataway, NJ, USA). sPLA2 assay kits were 
purchased from Cayman Chemical (Ann Arbor, MI, USA). Luria Burtani - broth 
and agar (Q.BIOgene, Irvine, CA, USA), QIAquick gel extraction kit (Qiagen, 
Hilden, Germany), HiFi polymerase (KAPA Biosystem, Cape Town, South 
Africa), Fast Digest Nde1 and Xho1 restriction enzymes, T4 DNA Fast 
Ligase, (Fermentas, Ontario, Canada), DNA Gene ruler (Fermentas, Ontario, 
Canada), pET-22b vector (Novagen, Merck biosciences), DNA oligos for 
amplification from 1
st
 Base Asia (Singapore), plasmid extraction kit (GeneAll 
plasmid miniprep kit, Korea), Big Dye (Life Technologies, Carlsbad, USA), 
Precision Plus Protein™ Dual-Colour Standards (Biorad, Hercules, CA, USA), 
acetonitrile and trifluoroacetic acid, formic acid (Merck KGaA,Darmstadt, 
Germany), Tris-HCl, Urea, NaCl from 1
st
 Base Asia (Singapore, Singapore), 
methanol (Merck chemicals, NY, USA), RP- Jupiter C18 columns (300 Å, 5 
μm, 250 mm X 21.2 mm and 250 mm X 10 mm) from Phenomenex (Torrance, 
CA, USA), Hi-Prep 16/60 gel filtration column and Hi-Trap-Sulfopropyl (SP)-




CHO-K1 cell line (American Type Culture Collection, Manassas, VA, USA), 
tissue culture plates (Corning, NY, USA), trypsin and trypsin neutralizer 
(GIBCO, Invitrogen, CA, USA), L-NAME, indomethacin, Dulbecco's 
Modified Eagle's Medium (DMEM), IBMX, saline, heparin (5000 IU/ml), 
penicillin-streptomycin, ODQ (Cayman Chemical, Ann Arbor, MI, USA), 
BSA (Sigma-Aldrich, St. Louis, MO, USA), sodium pentobarbital (NUS, 
Pharmacy, Comparative medicine). 
2.2.2 Cloning of prokaryotic PLA2 and mutants  
The DNA sequence encoding prokaryotic PLA2 in Escherichia coli was 
optimized for expression. The obtained synthetic gene was cloned using 
pUC57 vector. This gene fragment was amplified by both forward and reverse 
primers containing restriction sites Nco1 and Xho1, using the sequence from 
gene of interest. Synthetic DNA (0.1 μg) containing plasmid was amplified 
with 1 μl of 10 μM primer stock, 1 μl of 10 mM dNTPs, 1 unit of KAPA HiFi 
polymerase and 10 μl of 5X PCR buffer containing MgCl2 in a 50 μl reaction. 
The amplification cycling parameters were programmed to one cycle of 98 ºC 
for 2 min, 35 cycles of 98 ºC for 10 s, 60 ºC for 30 s and 72 ºC for 45 s, and a 
final extension at 72 ºC for 7 min. The product amplified was fractionated 
using 1% (w/v) agarose gel electrophoresis. The obtained product was 
extracted from the gel using the Qiagen gel extraction kit using the 
manufacturer’s protocol.  
Both DNA fragments and pET-22b (vector into which the DNA fragment is to 
be cloned) were double digested with Nco1 and Xho1 enzymes (1 unit enzyme 
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per μg DNA) for 30 min at 37 °C. Digested pET-22b was fractionated on 1 % 
(w/v) agarose gel and band corresponding to the linear plasmid was extracted 
from the gel. The double digested DNA fragment of PLA2 produced was 
subjected to PCR purification. Concentrations of the purified digested DNA 
fragments and the vector were estimated using NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies) with software ND-1000 V3.3.0. 
The DNA fragments (insert) and vector were ligated at 3:1 molar ratio. To 
ligate the DNA fragments with vector, 1 unit of T4 DNA ligase along with 2 
μl of 5X ligase buffer were added to the mixture  of a total volume of 10 μl 
and was incubated at 4 °C for overnight.  
 
The point mutations in the protein sequence were inserted by site directed 
mutagenesis. For the mutagenesis experiments, the desired mutations were 
incorporated into the forward and reverse primers designed specifically for 
this purpose. A PCR reaction was performed using the mutagenic primers 
following the protocol as described earlier. 20 μl of the reaction mixture was 
digested with Dpn1 enzyme at 37 °C for 1 h. 5 μl of this digested solution was 
used for transforming competent cells, as described below. Plasmid isolation 





2.2.3 Preparation of competent cells and transformation  
The competent cells for E. coli JM109 (copy number increase strain) and 
BL21 DE3 (expression strain) were prepared and used for experiments in this 
study. The cell stocks were thawed and streaked on antibiotic free LB agar 
plates and were grown at 37 °C for 16 h. The following day, a single colony 
from plate was inoculated in 2 ml of antibiotic free LB broth and was cultured 
at 37 °C, 200 rpm, 16 h. 1 ml of the overnight culture was used to inoculate 
100 ml of antibiotic free LB broth and was grown until the optical density 
(OD) at 600 nm reached a value between 0.6-1 OD at 37 °C, 200 rpm. The 
bacterial culture was poured into an ice-cold falcon tube and centrifuged at 
2000 g, 4 °C for 10 min. The supernatant was discarded as waste and the cells 
were resuspended in 1 ml of 100 mM CaCl2 that was further diluted to 50 ml 
with the same solution. This mixture was kept on ice for 40 min, following 
which it centrifuged at 2000 g, 4 °C for 10 min. The cell pellet was 
resuspended gently in 8-10 ml of 100 mM CaCl2 containing 10% glycerol 
(sterilized) and was split into 50 μl aliquots in pre-chilled 1.5 ml Eppendorf 
tubes.  
These prepared competent cells were transformed using the plasmid DNA. 
Vial containing cells was thawed on ice and the ligation mix was added and 
allowed to incubate on ice for 30 min. After incubation, the cells were 
subjected to heat shock at 42 °C for 90 sec and were immediately transferred 
on ice for 5 min. This was followed by the addition of 200 μl of LB broth to 
revive cells by incubating at 37 °C, 200 rpm for 30 min. This transformed 
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mixture was spread on ampicillin (100 μg/ml) containing LB agar plate. The 
plates were incubated at 37 °C for 16- 18 h. 
2.2.4 Plasmid isolation and DNA sequencing  
Isolated transformants from the plates were inoculated in 2 ml ampicillin (100 
μg/ml) containing LB broth and cultured for 16 h at 37 °C, 200 rpm. Plasmids 
were isolated from the cultured cells using GeneAll™ plasmid extraction kit, 
using the manufacturer’s protocol. Concentration of the DNA was estimated as 
described previously.  
The plasmid DNA was sequenced using ABI PRISM® Big Dye™ Terminator 
Cycle Sequencing Ready Reaction Kit (version 3.0) (PE-Applied Biosystems, 
CA, USA). Each 5 μl reaction constituted, 100 ng of plasmid DNA that was 
mixed with 2 μl of BigDye™ and 1 μM T7 promoter or terminator primers.. 
The reactions were amplified using the following conditions: 25 cycles of 
denaturation at 96 ºC for 10 s, annealing at 50 ºC for 5 s and extension at 60 ºC 
for 4 min. The PCR product was purified using Cleanseq magnetic beads and 
the purified DNA was dissolved in 40 μl of autoclaved water. The obtained 
DNA mixture was loaded on to automated ABI PRISM® 3130XL Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA). The sequences were 
analyzed using FinchTV and Generunner softwares. 
2.2.5 Expression of prokaryotic PLA2 
After validating the sequence, clones encoding the fusion protein were 
transformed into E. coli expression strain BL21 DE3 as described previously. 
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A single colony was inoculated in 100 ml of ampicillin (100 μg/ml) containing 
LB Broth and grown for 16 h at 37 °C at 200 rpm. This culture was used for 
inoculating 500 ml LB broth containing 100 μg/ml ampicillin in 1: 100 
(culture: broth) ratio and was grown at 37 °C, 200 rpm until the cell density 
reached ~ 0.6 OD at 600 nm. Protein expression was induced using 0.02 mM 
IPTG (isopropyl β-D-thiogalactoside) and the culture was grown further at 27 
°C, 150 rpm for 16-18 h. The cells were then harvested by spinning at 5,000 g 
for 15 min at 4 °C. Both cell pellet and the culture supernatant were checked 
for the expressed protein. The expression of recombinant protein was 
fractionated using SDS-PAGE on a 15% polyacrylamide gel.  
Bio-Rad Mini-PROTEAN™ gel system was used for running SDS-PAGE. 
Sample preparation was carried out by mixing 20 μl of sample and 5 μl of 5X 
loading dye and incubated the mixture at 100 °C for 10 min. The samples were 
centrifuged at 10, 000 g and 10 μl of this mixture was used for loading on to 
the gel. On the first lane molecular weight ladder, Precision Plus Protein™ 
Dual-Colour Standards (5 μl) was added. Electrophoresis separation was 
carried out at 120 V until the dye front reached the base of the gel. The gel 
was stained with Coomassie Brilliant Blue-R250 for the visibility of the 
protein bands.  
 
2.2.6 Purification of prokaryotic PLA2 
The expressed protein was purified in several steps. First the culture 
supernatant was fractionated by ammonium sulphate precipitation. The protein 
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was salted out at 50% ammonium sulphate saturation. Salt precipitation was 
performed at 4 °C by gradual addition of salt with continuous stirring. After 
completion of salt addition, the culture supernatant was stirred for additional 4 
h to ensure complete salt dissolution and precipitation. The saturated solution 
was next centrifuged at 8000 rpm (rotor radius =80 mm) for 30 min and the 
precipitate was dissolved in 10 ml deionised water. This salted out sample was 
further purified by gel filtration chromatography using Superdex 75 column 
(GE Healthcare Life Sciences, Little Chatfont, UK) in 50 mM Tris-HCl pH 8. 
The peaks from the purification profile were run on SDS-PAGE to confirm the 
presence of the expected protein. 
 
2.2.7 Cloning, expression and purification of PLA2-∆Helix KNP 
and PLA2-Denmotoxin 
For cloning the PLA2 fusion protein sequences, the two fragment genes were 
joined by extension overhang PCR technique with the incorporation of 
restriction sites, linker and protease cleavage sites. Briefly, the individual 
segments were amplified with specific primers designed such that the forward 
primer of the first segment contained the restriction site and reverse primer 
contained the linker and protease site sequences. For the second segment the 
forward primer contained the sequences complimentary to the linker and 
protease site and the reverse primer contained the restriction site. Following 
the first step of PCR amplification as described above, equal volumes of the 
two PCR products and the forward primer for the first segment and reverse 
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primer for the second segment were used in a second step PCR amplification 
as described earlier. The fusion gene was cloned by double digestion and 
ligation technique as described above. Strategies of expression involved were 
same as described above. The fusion proteins were purified by size exclusion 
chromatography as described above. The peak containing the fusion protein 
was identified by SDS-PAGE analysis and the mass of the fusion protein was 
analysed using Electrospray-ionization (ESI) - Mass Spectrometer (MS) (LCQ 
Fleet Ion trap, Thermoscientific, Massachusettes, USA). The fusion protein 
was next subjected to protease cleavage using recombinantly expressed and 
purified TEV protease in the ratio 50:1 (fusion protein:TEV protease) in 50 
mM Tris-HCl containing 0.5 mM EDTA pH 8, overnight at 4 °C. The 
cleavage product was purified by cation exchange chromatography, performed 
with 50 mM Tris-HCl pH 8 as buffer A and 50 mM Tris-HCl, 1 M NaCl pH 8 
as buffer B, on a Hi-Trap SP Sepharose column (34 μm, 16 X 25 mm). Next 
the cleaved protein peak of ion exchange chromatography was purified to 
homogeneity using RP-HPLC with Jupiter C18 column (5 μm, 300 Å, 250 mm 
X 10 mm) with buffer A- 0.01 % TFA and buffer B- 0.01% TFA with 100% 
Acetonitrile on a linear gradient of 20-40% B. Purified protein peak was 
analysed on ESI-MS for its purity and freeze dried. The protein was later 
reconstituted in phosphate buffer saline (PBS) and quantified by absorbance at 
280 nm before performing the assay. 
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2.2.8 Cell culture  
CHO-K1 cells was preserved in high-glucose Dulbeco’s modified eagle’s 
medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 100 
μg/ml streptomycin and 100 U/ml penicillin and 2 mM glutamine in a 
humidified incubator at 37 °C with 5% CO2. The cells were sub-cultured by 
trypsinization once every three days. The density of cells was obtained from 
Bio-Rad TC20™ automated cell counter.  
 
2.2.9 NPR-A plasmid preparation  
Plasmids encoding NPR-A and NPR-B were generously gifted by Prof. 
Micheala Kuhn (University of Wurzburg) and Dr. Ruey-Bing Yang 
(Academia Sinica). The plasmids were transformed into JM109 as reported 
previously. A single colony of the transformant was inoculated in 100 μg/ml 
ampicillin containing 100 ml of LB broth and was grown at 37 °C, 200 rpm 
for 22-24 h. The cells were harvested by centrifuging at 5,000 g for 20 min 
and the plasmids were extracted as per the manufacturer’s protocol using 
Pureyield™ plasmid maxiprep kit (Promega). The DNA concentration was 
estimated using nanodrop as described previously.  
 
2.2.10 Transfection of CHO-K1 cells  
1×10
5
 cells were seeded per well in a 24- well plate. The cells were grown for 
~20-22 h before transfection. The used media was aspirated from the wells and 
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refilled with 400 μl of DMEM containing 10% FBS without any antibiotics. 
Each well was maintained with 0.8 μg plasmid diluted in 50 μl of serum free 
DMEM media. Then 2 μl of lipofectamine™ 2000 was diluted in 50 μl of 
serum free DMEM media was added. Diluted DNA and transfection reagents 
were thoroughly mixed and allowed to stand at room temperature for 10-15 
min. The DNA- lipofectamine mixture (100 μl/ well) was directly transferred 
to the cells within 30 min. The cells were incubated with the DNA-lipid 
complex for 6 h at 37 °C with 5% CO2. After 6 h the media containing DNA 
and lipofectamine was aspirated and replaced with DMEM containing 10% 
FBS and antibiotics. These cells were incubated at 37 °C with 5% CO2 for 16- 
20 h before it was treated with the peptides.  
 
2.2.11 Whole cell cGMP elevation assay  
CHO-K1 cells transfected either with NPR-A/ NPR-B/ empty-vector 
pCMV4.0 were used for the experiments. Post transfection, aspirated media 
and cells were washed with 500 μl of PBS. The cells were incubated for 30 
min after adding 150 μl of 0.5 mM IBMX containing vascular growth media. 
Meanwhile, peptides were reconstituted in 4X concentrations. After incubation 
for 30 min, 50 μl of peptide solution was added to the cells, followed by 
further incubation for 30 min at 37 °C with 5% CO2. Subsequently, peptide 
containing basal media was removed and changed to 150 μl of 0.1 M HCl.This 
mixture was incubated at room temperature for 30 min with shaking at 50 rpm. 
The cell lysates were collected and the cGMP levels were estimated using 
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Enzo life sciences cGMP ELISA kit, as described in the manufacturer’s 
protocol. The total protein of the cell lysates from a few wells was estimated 
by BCA (bichinchonic acid) assay and the results were used to normalize 
across different 24 well plates used. Three independent experiments were 
carried out for each peptide and the statistical comparison between ANP and 
∆Helix KNP related peptides was conducted using one-tail ANOVA with t-













2.3.1 Expression and purification of wild type prokaryotic PLA2 
The wild type PLA2 was expressed and purified as a control. The enzyme was 
expressed by the optimized protocol described above (materials and methods). 
The culture was done in 2.8 l flask with 500 ml LB broth to provide sufficient 
head space for adequate aeration during the incubation. Following 18 h 
incubation at 27°C post induction, the culture was centrifuged and the 
supernatant was analyzed on SDS PAGE to confirm the extracellular 
expression of the wild type PLA2 (Figure 2.1 a). After confirmation of 
expression, the culture supernatant was salted out to 50% saturation by 
ammonium sulphate. The precipitate was purified by size exclusion 
chromatography by loading onto GE Superdex 75 prep column The protein 
peak indicated by an arrow (Figure 2.1 b) was analyzed by ESI LCMS to 
confirm the fully oxidized mass (Figure 2.1 c). After confirmation of the mass, 




Figure 2.1 Expression and purification of wild type PLA2 
A. SDS PAGE analysis showing extracellular expression of wild type PLA2.  
M- Marker, U- Uninduced whole cell lysate, B- Culture broth, C- Induced 
whole cell lysate. 
B. Purification of wild type PLA2 by size exclusion chromatography using 
superdex 75 prep column. 




2.3.2 Using full length PLA2 as a tag for extracellular export 
The prokaryotic PLA2 exhibited an unique property to be secreted into the 
extracellular medium, instead of its retention in the periplasmic space. 
Therefore our first aim was to use the full length molecule for the expression 
of other target proteins extracellularly. 

















































































































































13555.19   0.75 Da 
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2.3.2.1 Construct design to express PLA2-ProteinX extracellularly 
Since the prokaryotic PLA2 was exported to the extracellular media when 
expressed with pelB periplasmic signal, to use it as a tag to express other 
proteins in the culture media, the foremost thing was to design a general 
construct outline (Figure 2.2) where gene sequence corresponding to any 
protein of interest could be inserted. As shown in the figure, the segment 
containing the pelB signal, prokaryotic PLA2 and gene of interest ending with 
a stop codon would be then ligated in between Nde1 and Xho1 in pET 22b 
vector. 
 
Figure 2.2 Design of construct to use the full length PLA2 to express other 
proteins of interest 
General design of sequence of genes in the construct for extracellular 
expression. Gene sequences of pelB signal and prokaryotic pla2 are joined to 
the gene of interest with a linker containing the TEV protease site by overhang 
extension PCR. The entire gene construct is cloned between Nde1 and Xho1 in 
pET 22b vector. 
 
 
2.3.2.2 Design and cloning of PLA2-∆Helix KNP fusion gene in pET 22b 
vector 
In order to test our system for extracellular expression, the first test protein we 
selected was a natriuretic peptide, first identified from the cDNA library of the 
venom gland of Krait (Bungarus flaviceps). This molecule is small in size with 
pelB signal Gene of interest pkPLA2  
TEV Protease site 
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a molecular weight 3855.4 Da and relatively simple with only one disulphide 
bond (Figure 2.3).  
 
The ∆Helix KNP used in our study is a deletion mutant (residues 1-34) which 
lacks its short C-terminal helix, hence referred to as ∆Helix KNP. Although 
the molecule is relatively simple with respect to its structure, it was a difficult 
protein to express in E. coli. This molecule was unable to express in E. coli 
with 6x His tag and MBP tag, but could only be expressed with thioredoxin 
 
Figure 2.3 Structure of ∆Helix KNP 
Representation of structure of ∆Helix KNP, a molecule with a relatively 
simpler structure with one disulphide bond and molecular weight of 3855.4 
Da. 
 




tag as insoluble inclusion body protein as reported by earlier studies (Figure 
2.4) 
 
Figure 2.4 Expression of ∆Helix KNP-thioredoxin fusion protein 
SDS PAGE analysis showing the expression of ∆Helix KNP-thioredoxin 
fusion protein in the insoluble fraction in the form of inclusion body protein.  
M- marker, UI- uninduced, I- induced, S- soluble fraction of whole cell lysate, 
P- insoluble fraction of whole cell lysate. 
 
Therefore, as shown is the figure, despite being a relatively small and simple 
molecule, it was equally difficult to express it in soluble form using bacterial 
expression system. Moreover purification and recovery of the protein from the 
inclusion body involved multiple steps and the final refolded purified protein 
yield was as low as 0.2 mg from 50 mg of fusion protein. Therefore we 
considered to use this protein as the first target to validate the feasibility of the 
proposed expression system.  
Adapted from thesis, S. Sridharan 2014. 
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The gene construct was designed as explained earlier, by joining the pelB-
PLA2 gene with the gene sequence of ∆Helix KNP with the inclusion of a 
protease cleavage site. Tobacco Etch Virus (TEV) protease was selected as the 
protease of our choice due to its ease of expression in bacterial system in our 
lab. The construct design and the protein sequence of pleB-PLA2-∆Helix KNP 
with protease site is elaborated in Figure 2.5 a and b. 
 
Figure 2.5 Design of PLA2-∆Helix KNP gene for extracellular expression 
A. Schematic representation of a construct to express krait natriuretic peptide 
as a fusion partner of PLA2 (tag) with TEV protease cleavage site as a linker 
between the tag and the target protein.  
B. PLA2 - ANP fusion sequence with pelB signal and TEV protease site.  
Mature protein molecular weight is 18,187.1 Da. 
 
This fusion gene was constructed and amplified by overhang extension PCR 
followed by cloning into pET 22b vector between Nde1 and Xho1 site. Finally 
the sequences were confirmed by DNA sequencing analysis prior to 
expression. 











TEV protease cleavage point 
Start of mature protein pelB signal sequence 
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2.3.2.3 Expression and purification of PLA2-∆Helix KNP fusion protein 
The PLA2-∆Helix KNP fusion protein was expressed by the optimized 
protocol followed for the full length PLA2. After 18 h incubation at 27°C post 
induction, the culture was centrifuged and the supernatant was analyzed on 
SDS PAGE to confirm the extracellular expression of the fusion protein 
(Figure 2.6 a). The expressed protein in the culture supernatant was salted out 
by ammonium sulphate precipitation to 50% saturation. The salt precipitated 
protein was purified by size exclusion chromatography by loading on to GE 
Superdex 75 prep column (Figure 2.6 b). The fusion protein peak is shown by 
an arrow. The purified fusion protein was then run on ESI LCMS to analyze 
the molecular weight of the expressed protein (Figure 2.6 c). As shown in the 
figure, the molecular weight indicated the completely oxidized mass, giving us 
an idea that the fusion protein has formed all the 3 disulphide bonds, two from 
the tag (PLA2) and one from the target protein ∆Helix KNP. The total yield of 
the purified fusion protein was estimated by Bradford protein assay using BSA 





Figure 2.6 Expression and purification of PLA2-∆Helix KNP fusion 
protein 
A. SDS PAGE analysis showing extracellular expression of PLA2-∆Helix 
KNP.  
M- Marker, U- Uninduced whole cell lysate, IN- Induced whole cell lysate B- 
Culture supernatant, Asppt-Ammonium sulphate precipitate, GF-Protein peak 
from gel filtration chromatography. 
B. Purification of PLA2-∆Helix KNP by size exclusion chromatography using 
Superdex 75 prep column, black arrow showing the peak corresponding to the 
fusion protein. 
C. Mass of the protein determined by ESI Ion-Trap mass spectrometry . 
 
 
2.3.2.4 TEV protease cleavage of fusion and purification of ∆Helix KNP 
The fusion protein was subjected to TEV protease cleavage with a protein : 
protease ratio of 40:1 in the same buffer with 0.5 mM EDTA at 4°C for 16 h. 
The extent of cleavage is checked from SDS PAGE analysis (Figure 2.7 a) 


























































































































































































performed by taking an aliquot after the above mentioned incubation time. As 
seen from the SDS PAGE analysis, the fusion band had reduced considerably 
with the increase in the PLA2 tag band density, which gave us an approximate 
estimation of 80-90% cleavage efficiency. The cleavage reaction mix was next 
loaded on to a GE Hi trap SP HP cation exchange column, equilibrated with 
buffer A (50 mM Tris-HCl pH 8.0) and eluted with a linear gradient of 0-100 
% buffer B (500 mM NaCl in 50 mM Tris-HCl). Figure 2.7 b depicts the 
purification profile by cation exchange chromatography, the ∆Helix KNP 
elution peak is indicated by an arrow. This peak was re-chromatographed by 
reversed phase chromatography by loading the sample onto a Jupiter C-18 
analytical column (Figure 2.7 c). The purified ∆Helix KNP peak, shown by an 
arrow, eluted at around 30% B (buffer A: 0.1% TFA, buffer B: 0.1% TFA, 
100% acetonitrile). The purified ∆Helix KNP was analyzed by ESI MS, which 
showed the expected oxidized mass (Figure 2.7 d). The peak was pooled and 
freeze dried. Later the freeze dried protein was reconstituted in 1x PBS for 
protein estimation and assay for biological activity. The total recovered ∆Helix 




Figure 2.7 TEV protease cleavage of PLA2-∆Helix KNP fusion protein 
A. SDS PAGE analysis showing TEV protease cleavage of PLA2-∆Helix KNP 
fusion protein.  
M- Marker, Unclv- Uncleaved fusion protein, Clv- Cleavage products after 16 
h incubation at 4°C.  
B. Purification of the cleavage products by cation exchange chromatography 
using Hi-trap SP HP column, black arrow showing the peak corresponding to 
∆Helix KNP. 
C. Reversed phase chromatograpy of the peak from cation exchange 
purification, using Jupiter C18 column. 
D. Mass of the protein determined by ESI Ion-Trap mass spectrometry. 
 
 
2.3.2.5 Co-expression of truncated PLA2-∆Helix KNP fusion protein 
Along with the fusion protein, we observed the expression of a second band of 
protein of mol. wt. between 10-15 kDa (based on the SDS PAGE marker), 
circled in Figure 2.8 a. We wanted to identify the protein as it consistently co-
expressed in all batches of culture. Therefore we analyzed the protein by ESI 


































































































































































LCMS and deduced the mass of the protein (Figure 2.8 b). From the estimated 
molecular weight and the sequence of the fusion protein, the extra band of co-
expressed protein was confirmed to be a truncated fusion protein, which stops 
just after the TEV protease cleavage site (Figure 2.8 c). The exact reason for 
the truncated protein expression though unclear to us, similar phenomenon is 
observed in the case of heterologous expression of complex proteins with 
well-known solubilization tags such as MBP and GST. Therefore most likely, 
∆Helix KNP being a difficult to express target protein, exhibits similar 




Figure 2.8 Co-expression of truncated PLA2-∆Helix KNP fusion protein 
A. SDS PAGE analysis showing the truncated protein band (circled) of the 
fusion containing only the PLA2 tag without ∆Helix KNP.  
M- Marker, U- Uninduced whole cell lysate, IN- Induced whole cell lysate B- 
Culture supernatant, Asppt-Ammonium sulphate precipitate, GF-Protein peak 
from gel filtration chromatography. 
B. Mass of the protein determined by ESI Ion-Trap mass spectrometry. 




2.3.2.6 Assay for biological activity of ∆Helix KNP 
After purifying the expressed and cleaved ∆Helix KNP to homogeneity, we 
further wanted to evaluate if the protein expressed using this system retains the 
same function as reported earlier. Therefore we went ahead to check its 
function by performing a cell-based assay. CHO K1 cells were transfected 
with plasmid containing NPR-A receptor gene, leading to the expression of 
NPR-A receptors on the CHO K1 cells. These cells were then treated with 
∆Helix KNP in a dose dependent manner. The interaction of ∆Helix KNP with 









































































































TEV protease cleavage point 





NPR-A receptors led to cGMP response, which was measured. From the 
assay, the cGMP response elicited by ∆Helix KNP was 300 pmol/ml less than 
standard ANP, which is comparable to the earlier reported values (Figure 2.9). 
Therefore the ∆Helix KNP expressed by this method had a yield 2.5 times 
higher than the earlier reported values and retains the same biological activity. 
 
Figure 2.9 Functional assay for ∆Helix KNP 
cGMP response of ∆Helix KNP compared with the standard ANP. cGMP 
response evoked by ∆Helix KNP was shown to be comparable to the reported 































Concentration of peptides (nM)  
ANP
ΔHelix-KNP 
n = 2 
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2.3.2.7 Design and cloning of PLA2-Denmotoxin fusion gene in pET 22b 
vector 
After our success with the extracellular expression of ∆Helix KNP using PLA2 
as a tag, we wanted to extrapolate this technique to test other target proteins 
with increased complexity. To test our system of extracellular expression 
using PLA2 as a tag our next selected target protein was a three-finger toxin, 
denmotoxin. Denmotoxin is a three-finger neurotoxin from Boiga 
dendrophila. This molecule is relatively more complex than ∆Helix KNP, with 




Figure 2.10 Crystal structure of denmotoxin (2H5F) 
Representation of crystal structure of denmotoxin, a molecule with a relatively 




Design of the gene construct and cloning into pET 22b vector was the same as 
followed in case of ∆Helix KNP, with the exception of addition of three extra 
glycines at the C-terminus of PLA2 tag, which give a little more space for the 
access of the cleavage site by TEV protease. The construct design and the 






Figure 2.11 Design of PLA2-DTX gene for extracellular expression 
A. Schematic representation of a construct to express denmotoxin as a fusion 
partner of PLA2 (tag) with TEV protease cleavage site as a linker between the  
tag and the target protein.  
B. PLA2 - DTX fusion sequence with pelB signal and TEV protease site.  
Mature fusion protein molecular weight is 23153.8 Da. 
 
 
2.3.2.8 Expression and purification of PLA2-DTX fusion protein 
PLA2-DTX fusion protein was expressed using the same protocol followed in 
case of PLA2-∆Helix KNP. The SDS PAGE analysis of the culture supernatant  
(Figure 2.12 a) showed a band between 20-25 kDa. The culture supernatant 
was salted out to 50% saturation with ammonium sulphate. The precipitate 
was loaded on to GE superdex 200 prep column. The fusion protein peak is 
marked with an arrow in the chromatogram shown in Figure 2.12 b. The gel 
filtration peak was analyzed by ESI-LCMS and the molecular weight 
estimated was 23153.8 Da (Figure 2.12 c). The mass corresponds to the exact 













TEV protease cleavage point 
Start of mature protein pelB signal sequence 
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expected oxidised mass of the fusion protein, taking into consideration the two 
disulphides in the tag and five disulphides in the target protein. This gave us 
an initial idea that the protein might be folded correctly, although cleavage of 
the tag and assessment of biological activity would confirm it. Moreover, the 
truncated PLA2 tag was not found in case of this fusion protein expression. For 
estimating the yeild of the fusion protein, Bradford method was not followed 
due to the presence of contaminating proteins from the previous peak in the 
gel filtration elution, which would overestimate the total fusion protein. So we 
went ahead to calculate the yield from the total PLA2 activity in the culture 




Figure 2.12 Expression and purification of PLA2-DTX fusion protein 
A. SDS PAGE analysis showing extracellular expression of PLA2-DTX.  
M- Marker, U- Uninduced whole cell lysate, IN- Induced whole cell lysate B- 
Culture supernatant, Asppt-Ammonium sulphate precipitate. 
B. Purification of PLA2-DTX by size exclusion chromatography using 
superdex 200 prep column, black arrow showing the peak corresponding to the 
fusion protein. 
C. Mass of the protein determined by ESI Ion-Trap mass spectrometry. 
 
 
2.3.2.9 TEV protease cleavage of PLA2-DTX fusion protein 
The fusion protein was set for cleavage reaction with TEV protease, using the 
same ratio of protein : protease as described earlier. But unfortunately, the 
fusion protein was resistant to TEV protease even after increasing the protease 
concentration in the cleavage reaction (Figure 2.13 a). We observed the 
































































































































































































23153.88   1.06 Da 
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hence the ineffectiveness of TEV protease was thought to be due its lesser 
availability in the cleavage reaction due to precipitation. 
 
Figure 2.13 TEV protease cleavage of PLA2-DTX fusion protein 
SDS PAGE analysis of TEV protease cleavage reaction of PLA2-DTX fusion 
protein. 
M- Marker, Unclv- Uncleaved fusion protein, Clv- Cleavage products after 16 
h incubation at 4°C, Sup-supernatant after centrifuging the cleavage reaction, 
Ppt-precipitate, TEV-TEV protease used in cleavage reaction, for reference.  
As seen from the SDS PAGE analysis, no cleavage occurred after incubation 
with TEV protease. Moderate precipitation was observed, which was due to 
precipitation of TEV protease. 
 
 
 Therefore our first troubleshooting step was to change the TEV site in the 
construct with a protease which has a better solubility when compared to TEV. 






M    Unclv   Clv    Sup     Ppt   TEV     M 
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2.3.2.10 Swap of cleavage site and HRV 3C protease cleavage of PLA2-
DTX fusion protein 
The cleavage site was swapped with HRV 3C protease site as shown in Figure 
2.14 a. After cloning the gene with the new protease site, followed by its 
expression and purification as described earlier for the same fusion with TEV 
site, the cleavage of the fusion was performed. But unfortunately, the fusion 
protein showed resistance to cleavage with HRV 3C protease site, even at a 




Figure 2.14 HRV 3C protease cleavage of PLA2-DTX fusion protein with 
HRV 3C protease site 
SDS PAGE analysis of HRV 3C protease (marketed as prescission protease by 
GE) cleavage reaction of PLA2-DTX fusion protein. 
M- Marker, Unclv- Uncleaved fusion protein, Clv- Cleavage products after 16 
h incubation, Clv+- Cleavage performed in presence of 1 mM DTT 
A. Sequence of TEV protease site (top) and HRV 3C protease site 
(bottom) compared. 
B. Cleavage reaction performed at 4°C 
C. Cleavage reaction performed at 25°C 
As seen from the both the SDS PAGE analysis, no cleavage occurred after 
incubation with HRV 3C protease.  
 
 
Therefore the problem might be related to the linker, being of insufficient 
length for the access of the protease at the cleavage site due to stearic 
hindrance. Our current experiments are focused on increasing the linker length 
between the PLA2 tag and target protein.  



















With this we move into the next aim of the chapter, to identify minimum 
region of the PLA2 which retains the property of extracellular export. 
 
 
2.3.3 Study of minimal region of PLA2 required for export 
Since the whole molecule was able to express target proteins extracellularly in 
reasonable amounts, we wanted to recognize minimum region of the molecule 
which could hold on to the property of extracellular secretion. This would not 
only make the tag smaller, reducing the burden of cellular resources used by 
the bacteria to synthesize the tag itself, but also give us insights about the 
region of the molecule responsible for the export. Moreover, if minimal PLA2 
domains could be expressed extracellularly, it could be readily assessed for 
function, which is the scope of our later part of the study regarding designing 
of minimized PLA2 scaffolds, elaborated in the 3
rd
 chapter of the thesis. 
 
2.3.3.1 Design of truncated mutants to identify minimal region 
responsible for the export 
To identify minimal region for export, truncated mutants were generated 
(Figure 2.15). As shown in this figure, the wild type enzyme is compared with 
the various truncated mutants generated. The first mutant is Helix 1 & 2 with 
only the first two helices (Figure 2.15 B, b). The second mutant is ∆ Helix 1 & 
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2 in which the first two helices are removed (Figure 2.15 C, c). The third 





was done to make the helices shorter by one turn each, with a total reduction 
of 8 residues, as a strategy for minimizing the enzyme (Figure 2.15 D, d). 
Cloning was done in pET 22b in the same fashion as described for the full 
length enzyme. 
 
Figure 2.15 Design of truncated mutants to identify minimal region for 
export 
A and a. Wild type enzyme 
B and b. Helix 1 & 2 
C and c. ∆ Helix 1 & 2 




∆ Helix  1 & 2 










Figure 2.16 Construct  designed with proposed minimal segment to use as 
extracellular expression system 
A schematic representation of a construct designed to use as extracellular 
expression system. The proposed segment is the domain we wanted to 
identify, which was anticipated to responsible for exporting the molecule  
form the periplasmic space to the extracellular medium. 
 
 
2.3.3.2 Expression of Helix 1 & 2 in pET22b with pelB signal sequence 
Expression of Helix 1 & 2 was done in the same way as described for the wild 
type. As shown in the SDS PAGE analysis (Figure 2.17) there was no 
difference between the uninduced and induced whole cell lysate, indicating no 
expression of the mutant. 




Figure 2.17 Expression of Helix  1 & 2 in pET22b with pelB signal 
sequence 
SDS PAGE analysis  showing  the expression profile of  helix 1 & 2.  
M-marker, UN-uninduced, IN-induded, B-culture supernatant.   
Induced lane shows no difference from the uninduced lane,  
confirming no expression of the  construct with helix  1 & 2  
 
 
2.3.3.3 Expression of ∆ Helix  1 & 2 in pET22b with pelB signal sequence 
Expression of ∆ Helix 1 & 2 was done in the same way as described for the 
wild type. As shown in the SDS PAGE analysis (Figure 2.18) the mutant was 
expressed but was found in the insoluble fraction of the whole cell lysate, 
indicating the formation of inclusion body protein. Expressed protein was not 




Helix 1 & 2 
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found in periplasmic space. Therefore the lack of the two N-terminal helices 
led to misfolding of the mutant resulting in the formation of inclusion body. 
 
Figure 2.18 Expression of ∆ Helix  1 & 2 in pET22b with pelB signal 
sequence 
SDS PAGE analysis  showing  the expression profile of  ∆ helix 1 & 2.  
M-marker, Un-uninduced, Ind-induced, Sol- soluble fraction of whole cell 
lysate, Insol- Insoluble fraction, containg inclusion body proteins, 
Broth-culture supernatant, Suc-sucrose, Peri-periplasmic fraction.   
∆ helix  1 & 2 expresses with the pET22b-pebB construct, but is found in the 
insoluble fraction.  
No expression is seen in the culture supernatant and periplasmic fraction. 
Formation of inclusion body protein is due to lack of proper folding of the ∆ 
helix  1 & 2 in absence of  the N-terminal helices. 
 
 
M      Un     Ind      Sol    Insol   Broth   Suc    Peri   
15 kDa 
10 kDa 
∆ Helix  1 & 2 
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2.3.3.4 Expression of Helix-short PLA2 in pET22b with pelB signal 
sequence 
Expression of Helix-short PLA2 was done in the same way as described for the 
wild type. As shown in the SDS PAGE analysis (Figure 2.19 a and b) the 
mutant was expressed and found in the soluble fraction of the whole cell 
lysate. Periplasmic protein preparation showed the presence of expressed 
protein in periplasmic space. No protein expression was observed in the 
culture supernatant. Therefore with the shortened helices, the mutant was able 
to enter the periplasmic space but unable to cross the outer membrane to get 
secreted to the extracellular medium. Therefore the N-terminal helices seems 
to help improve the solubility of the protein allowing it to enter the periplasm, 
but probably lacks the structural features which is needed to secrete the protein 




Figure 2.19 Expression of Helix-short PLA2 in pET22b with pelB signal 
sequence 
SDS PAGE analysis  showing  the expression profile of  Helix-short PLA2 .  
A. SDS PAGE depicting expressed protein present in soluble fraction.  
B. SDS PAGE of periplasmic protein preparation  showing soluble protein is 
retained in the periplasmic space. 
M-marker, Un-uninduced, Ind-induced, Sol- soluble fraction of whole cell 
lysate, Insol- Insoluble fraction, containg inclusion body proteins, 
Broth-culture supernatant, Suc-sucrose, Peri-periplasmic fraction.   
Helix-short PLA2 expressed with the pET22b-pebB construct, and was found 
in the soluble fraction. No expression was seen in the culture supernatant but 
the periplasmic fraction contained the Helix-short PLA2. The N-terminal 
helices are thus required for the solubility and folding , hence the Helix-short 
PLA2  was retained in periplasm. But the changes in the tertiary structure due 




Therefore from the above experiments although we were unable to identify the 
minimal segment responsible for the export, we were able to get clear 
information about the role of N-terminal helices in improving the solubility of 
the expressed mutants. Next we wanted to check the expression level of the 
tag with point mutants in different culture conditions, elaborated in the 
following section. 












2.3.4 Effect of point mutations and temperature on expression of 
the tag (PLA2) 
To design an expression system, the properties of the tag and its behavior in 
different culture conditions is very important. The tag should be studied 
thoroughly and its expression itself optimized carefully. In this section we 
studied the properties of the tag with respect to point mutations and culture 
temperature. 
2.3.4.1 Point mutations in pET22b-PLA2 plasmid 
The basis of incorporation of point mutations in the PLA2 comes from the aim 
of the 3
rd
 chapter of the thesis, i.e., to design a minimal PLA2 scaffold. Point 
mutations were introduced to aid chemical cleavage of the mutant full length 
molecule, which could be expressed in large amounts with pelB in 
extracellular medium. Following the purification of full length mutant 
molecule, it could be subsequently cleaved by specific chemicals leading to 
the generation of small scaffolds. The first strategy was to introduce a 
cyanogen bromide cleavage point after the first two N-terminal helices which 
would retain the three-helix catalytic core and the calcium binding loop. The 
mutations incorporated were A35M, M92L, first mutation being the CNBr 
cleavage point at 35
th
 position and the second mutation at 92
nd
 position to 





Figure 2.20 Point mutations in pET22b-PLA2 plasmid 
Point mutations designed for chemical cleavage of full length PLA2, to make a 
small scaffold.  
Expression of these mutants gave us information about optimal culture 
conditions for expression of the molecule as an extracellular expression tag. 
 
 
Expression of the double mutant at culture conditions reported by earlier 
studies at 37°C, led to the decrease in yield by 80% compared to the wild type 
enzyme expressed in the same conditions (Figure 2.21 a). Two mutations 
leading to decrease in yield by 80% was intriguing, hence we wanted to pin 
point the mutation which led to the drastic decrease in the export. This was 
done by expressing the individual single mutants at the same culture condition. 
But from the yield information it was evident that the effect of double 
mutation was additive when compared to the single mutation. 
Next we wanted to understand if the mutations in the enzyme led to its 
decrease in expression or decrease in export due to its possible retention in the 
cell. SDS PAGE analysis performed with the whole cell lysate (Figure 2.22) 
showed that the mutations caused the misfolding of the protein leading to 
formation of inclusion body, hence retained in the cytoplasm. This is evident 
from the insoluble fraction in the SDS PAGE analysis which shows the 
retention of the expressed protein in the cytoplasm in the form of inclusion 
M92L 




body. Therefore the mutations caused the misfolding leading to decreased 
extracellular secretion and did not reduce the expression of the enzyme. 
 
Figure 2.21 Expression of wild type PLA2 and mutants at different 
incubation temperature 
A. Bar graph showing the expression of PLA2 mutants compared to the wild 
type at different incubation temperature. 




2.3.4.2 Expression of wild type PLA2 and mutants at different incubation 
temperature 
Hence after understanding the effect of point mutations in the formation of 
insoluble enzymes, the wild type and the mutants were optimized for yield at 
27°C and 18°C for 16-18 h. Culturing at 18°C further reduced the yield 
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Point mutants cultured at 18°C 
37°C 27°C 16°C 
Wild type 4.08 8.27 2.49 
A35M 2 4.39 1.35 
M92L 2.13 2.68 0.82 
A35M-M92L 0.82 2.54 0.49 
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whereas culturing at 27°C doubled the yield of wild type and the double 
mutant Figure 2.21 a and b). Therefore from these series of experiments we 
were able to standardize the optimal expression condition for the wild type and 
mutants, which is an important information when considering the expression 




Figure 2.22 SDS PAGE analysis of wild type and mutant PLA2 expression 
SDS PAGE analysis showing the expression of wild type and mutant PLA2.  
Point mutations in the molecule led to misfolding of the mutant PLA2, leading 
to the formation of inclusion body, as seen in the insoluble fraction of the 
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In this chapter, we could demonstrate the use of prokaryotic PLA2 as an 
extracellular expression tag. The first target protein we tested with this system 
was ∆Helix KNP. After cleavage of PLA2-∆Helix KNP fusion, the purified 
∆Helix KNP was found to be biologically active. The yield of the final 
refolded target protein (∆Helix KNP) was shown to be 2.5 times higher 
compared to the yield obtained by recovering the protein from the inclusion 
body, as reported earlier (Thesis, S. Sreedharan, 2014). Moreover fewer 
purification steps to obtain the pure protein compared to the conventional 
methods are an added advantage. Although from ~14 mg of fusion protein we 
could obtain ~0.5 mg purified ∆Helix KNP, two points worth mentioning for 
the final protein yield. First, around 50% of the total fusion protein is a 
truncated tag moiety co-expressed, hence the starting intact (full length) fusion 
can be considered to be roughly about 7 mg. Second, the ∆Helix KNP moiety 
is around 3 kDa compared to the fusion, which is around 18 kDa, therefore the 
expected mount of cleaved product (∆Helix KNP) obtained theoretically 
would be around 1.2 mg. Finally after two purification steps following 
cleavage, the final yield of 0.5 mg is reasonable although single step reversed 
phase purification might allow better recovery.  
During the expression of PLA2-∆Helix KNP as explained above, we observed 
the expression of a truncated fusion protein (section 2.3.1.5), which was later 
identified to be a part of the fusion protein with the C-terminus segment after 
the TEV protease site absent. Truncated proteins are usually produced due to 
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the use of rare codons in genes not well optimized for expression in E. coli 
(Kane, 1995). Although the gene sequence used for ∆Helix KNP expression 
was optimized for expression in E. coli, the truncated fusion was produced. 
Nevertheless these kinds of truncations are also seen occasionally with 
heterologous protein expression in E.coli, using other soluiblization tags such 
as GST or MBP, where only the tag moiety is seen to express along with the 
fusion protein. The reason behind this phenomenon being unclear, it is often 
speculated to be an issue when the bacteria fail to translate the complete fusion 
containing a heterologous protein which is complex/difficult for the bacteria to 
express. Therefore after translating the tag which is usually an endogenous, 
highly soluble bacterial protein, the process stops leading to the formation of 
truncated proteins.  
Since the tag is an active PLA2 enzyme, this kind of truncated fusion protein 
production containing only the tag, would not allow the extracellular 
expression system to be used to readily estimate the protein yield from the 
total activity in the culture broth. In other words, expression of the tag along 
with the fusion would overestimate the yield if total activity is considered for 
estimating total fusion protein yield. Nevertheless for target proteins where no 
truncated fusion is produced (for example, PLA2-Denmotoxin) estimating total 
activity and correlating with the expression yield could provide additional way 
to assess the extent of expression and provide a tool for expression 
optimization by studying the time course of expression. Commercially 
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available PLA2 assay kits might be used for simple and quick assessment of 
expression. 
 The failure of the cleavage of PLA2-Denmotoxin fusion with both TEV and 
HRV 3C protease (figure 2.12, 2.13) necessitates the need for increasing the 
linker between the tag and the target protein. The problem was seen in the 
denmotoxin fusion protein as the earlier expressed ∆Helix KNP had relatively 
simpler structure which probably provided ample space for the protease to act 
on the site. More work is needed in this area to figure out the optimal linker 
length for efficient cleavage of fusion protein. 
Our next part of the study involved the identification of minimal segment 
which could retain the property of extracellular export. Although the mutants 
designed to identify the minimal segment were not secreted into the 
extracellular medium, we could understand other properties of the molecule 
and the importance of the N-terminus two-helix bundle in the solubility of the 
molecule. The ∆ Helix 1 & 2 misfolded as inclusion body whereas the Helix 
short PLA2 was able to express as soluble protein and enter the periplasmic 
space, but not secreted into the extracellular medium. This could give us 
information regarding the necessity of the N-terminal two helixes in enhancing 
solubility of the protein and in the same time the subtle changes in the 
structure of the Helix short mutant, which could forbid it from secreting into 
the extracellular medium. Studying this mutant further may give us 
information regarding the region or fold of the molecule which might interact 
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with some unknown partners of the bacterial secretion systems to aid its 
secretion into the extracellular medium. 
The point mutations on PLA2, although incorporated for structural 
minimization (the focus of chapter 3) by chemical cleavage, provided us a 
model to test effect of mutations on PLA2 secretion. Initial observations of 
highly reduced yield of mutant (A35M-M92L) due to the presence of only two 
point mutations made us question whether the mutations causes the reduced 
expression or reduced export to the extracellular medium. Though the 
mutations in the molecule did not affect the expression, it led to misfolding at 
37°C causing the decrease in the amount of enzyme secreted. On the other 
hand, lowering the temperature to 27°C increased the yield of the mutants by 2 
folds. Further reduction of the incubation temperature to 18°C led to much 
decrease in the protein yield. These experiments also concluded that the 
maximum protein yield could be obtained by reducing the culture temperature 
to 27°C and extending the incubation time to 18 h.  
Overall, we could develop an extracellular expression system exploiting the 
unusual property of secretion of prokaryotic PLA2 into the culture medium. 
This system seems to be helpful in expression of disulphide rich proteins in 
soluble and correctly folded form. The secretion property would reduce the 
downstream purification steps and provide the added benefit of assessment of 
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3 CHAPTER THREE: Design of a mini PLA2 scaffold 
3.1 Introduction 
Mini proteins or protein domains are considered to be the smallest functional 
unit of a protein. Protein minimization, a type of protein engineering endeavor, 
help us understand the first principles of protein folding, structure-function 
relationship and design of stable scaffolds. 
Mini proteins serve as stable scaffolds which can be used as a starting template 
for the design of other useful molecules. Desired function can be imparted into 
small scaffolds by grafting of active sites (Stricher et al., 2006). Small stable 
scaffolds with a desired biological activity can be used for the design of other 
modular biologics or biotechnological tools.  
The prokaryotic PLA2 is structurally very unique. It is the first PLA2 described 
with least structural complexity (Matoba et al., 2002). Unlike other secretory 
PLA2s which has five to seven disulphides, the prokaryotic enzyme has only 
two disulphides. Moreover this enzyme retains the same topologically 
conserved three-helix catalytic core seen in secretory PLA2 enzymes. The 
three dimensional structure of the prokaryotic enzyme shows the presence of a 
N-terminal two-helix bundle protruding away from the three helix catalytic 
core. With these structural features, the prokaryotic enzyme provided us a 
model to attempt the design of a mini scaffold with just the three-helix 
catalytic core and at the same time, trying to retain its enzymatic activity. 
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The prokaryotic PLA2 is one of the smallest PLA2 enzymes with a molecular 
weight of 13.5 kDa. Being a small enzyme and possessing structural regions 
which seemed to be unnecessary for its enzymatic activity, we minimized the 
enzyme from the N-terminus, by removing the two-helix bundle to make a 
scaffold with a molecular weight of 9.1 kDa. Although the smallest mutant (∆ 
Helix 1 & 2) was 32% smaller in size compared to the wild type, it completely 
lost its enzymatic activity. In order to regain its activity, we re-designed the 
same mutant by altering the hydrophobic surface with polar residues. 
Although we failed to regain or improve the function of this 2
nd
 generation 
mutant, we are trying to crystallize the smallest mutant, which may give us 









3.2 Materials and Methods 
3.2.1 Materials  
Many materials used in the experiments described in this chapter are already 
mentioned in the previous chapter. Apart from those, pET-21a vector 
(Novagen, Merck biosciences), DTT and reduced/oxidised glutathione 
(Nacalai Tesque, Kyoto, Japan), Trypsin Gold, Mass Spectrometry Grade 
(Promega corporation, Madison, Wisconsin, USA), crystallization screens, 
crystallization trays, coverslips and grease were purchased from Hampton 
Research (Aliso Viejo, CA, USA). Other reagents and chemicals used in the 
experiments were of analytical grade. 
3.2.2 Cloning of prokaryotic PLA2, wild type and minimized 
mutants  
The optimised gene sequence was obtained as described before. Cloning of the 
wild type and minimized mutants were done in pET-21a vector between Nde1 
and Xho1 restriction sites. Other cloning and mutagenic methods followed are 
same as described before. 
3.2.3 Expression of prokaryotic PLA2, wild type and minimized 
mutants  
Most of the bacterial expression protocol is same as described earlier. The 
expression conditions were altered for aiding the formation of inclusion body 
proteins. At OD600 = 0.6, the culture was induced to 500 mM IPTG and 
incubated at 37°C for 5-6 hours. 
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3.2.4 Inclusion body preparation 
Since the protein was expressed as inclusion body, which forms a major part 
of the insoluble fraction of the cell lysate, the inclusion body protein was first 
partially purified from the other cellular debris by giving several washes with 
a buffer containing detergent (50 mM Tris pH 8, 1 mM EDTA, 2% sodium 
deoxycholate). For each of the washes, the insoluble fraction was dissolved by 
sonicating for 2 min with the detergent buffer, followed by centrifugation of 
the dissolved insoluble fraction containing the inclusion body. This cycle was 
repeated for a total of three times, which led to the reduction of other 
contaminating proteins in the preparation. 
3.2.5 Refolding wild type and minimized mutants 
The inclusion body proteins obtained from 1 l culture were first dissolved in 
10 ml of denaturing buffer containing reducing agent (100 mM Tris pH 8, 6 M 
guanidine hydrochloride, 100 mM DTT). The solubilized inclusion body 
solution was incubated for 3-4 h on a rocker at room temperature to ensure 
complete denaturation and reduction of the disulphide bonds in the proteins. 
Next the pH of the solution was reduced by addition of 0.1 ml of concentrated 
HCl, to inhibit disulphide shuffling. This solution was dialyzed against 2 l 
buffer ( 20 mM acetic acid, 4 M guanidine hydrochloride) for 16 h to remove 
the reducing agent DTT before proceeding for refolding. The dialysed protein 
was quantified by Bradford protein assay and used for refolding at a 
concentration of 50 µg/ml. To confirm the complete reduction of the 
disulphide bonds in the proteins, an aliquot was taken for molecular mass 
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determination by ESI- LCMS (LCQ Fleet Ion trap, Thermo Scientific, 
Massachusettes, USA).  Optimal refolding condition was screened with the 
refolding buffer containing additives like arginine and glycerol, the final 
condition used for refolding the wild type and the mutants was 0.5 M Tris pH 
8, 10 mM CaCl2, 1 mM EDTA, 1 mM oxidised glutathione and 5 mM reduced 
glutathione. Refolding was performed by the dilution technique, where the 
reduced and denatured protein was diluted to the final refolding concentration 
by adding the protein slowly into the pre-chilled refolding buffer. The 
refolding solution was then incubated at 4°C for 48 h. 
3.2.6 Purification of refolded wild type and mutants 
Purification of the refolded proteins were performed by reversed phase 
chromatography using Akta system (GE Healthcare Life Sciences, Little 
Chatfont, UK). Refolding solution was directly loaded onto reversed phase 
column (Jupiter C18, 5 μm, 300 Å, 250 mm X 10 mm) with buffer A- 0.01 % 
TFA and buffer B- 0.01% TFA with 100% Acetonitrile on a linear gradient of 
24-45% B. The elution profile was monitored at 280 nm. The purified protein 
was analysed by ESI- LCMS (LCQ Fleet Ion trap, Thermo Scientific, 
Massachusettes, USA) for assessing complete refolding which is indicated by 
the reduction in the molecular weight due to loss of hydrogen as a result of 
disulphide bond formation. 
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3.2.7 CD spectroscopy 
CD spectra (Far-UV, 260-190 nm) were recorded using a spectropolarimeter 
(Jasco J-810, Jasco Corporation, Tokyo, Japan). The wild type and the mutant 
protein at a concentration of 0.25 mg/ml was dissolved in 5 mM phosphate 
buffer pH 7.5 and placed in a quartz cuvette with 0.1 cm path length. The 
instrument optics and cuvette chamber were purged continuously with 
nitrogen gas during the entire span of the experiment to provide an oxygen-
free environment. The spectra were recorded with data pitch of 0.1 nm, a 
bandwidth of 1 nm and at a scanning speed of 50 nm/min. To increase the 
signal to noise ratio, an average of three scans was taken and finally the 
baseline was subtracted with a blank reading. 
3.2.8 Disulphide bond determination 
The disulphide bonding pattern in the refolded mutants were determined by 
cleavage of the protein by trypsin (Trypsin Gold, Mass Spectrometry Grade 
(Promega corporation, Madison, Wisconsin, USA) followed by analysing the 
mass of peptide containing the disulphide bonds. The mutant proteins were 
dissolved in 50 mM phosphate buffer pH 7 at a concentration of 0.2 mg/ml. 
The cleavage reaction was set in a 200 µl reaction tube with the protein: 
protease ratio of 50:1. The cleavage solution was incubated at 37°C for 16 h. 
After the completion of incubation, the cleavage solution was analysed by 
ESI-LCMS (LCQ Fleet Ion trap, Thermo Scientific, Massachusettes, USA), 
using a Aeris (C18, 5 μm, 300 Å, 250 mm X 2.1 mm) reverse phase column 
with buffer A- 0.01 % FA and buffer B- 0.01% FA with 100% Acetonitrile on 
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a linear gradient of 5-40% B over 60 min at a flow rate of 0.4 ml/min. The 
peptide masses obtained were analysed and compared against the theoretical 
expected mass of the peptides containing the disulphide bonds. Presence of the 
disulphide bonds were confirmed by the reduction in the molecular weight by 
2 Daltons in the peptide mass. 
3.2.9 Crystallization 
Crystallization conditions for ∆Helix 1 & 2 were screened with different 
crystallization screens (Crystal Screen 1, Crystal Screen 2, Index, Wizard 1, 
Wizard 2, Wizard 3, Wizard 4, JCSG 1, JCSG 2) using a sitting-drop vapour-
diffusion method. The lyophilized protein was dissolved in deionised water 
due to its poor solubility in any buffered solution after reversed phase 
purification. The protein concentrations used for setting the drops were 5 
mg/ml and 20 mg/ml. The drops were set by Mosquito crystallization robot, by 
mixing equal volume (0.4 μl each) of protein and crystallization solutions. 
Each well was filled with 80 μl of respective reservoir solution (crystallization 
solution). The plates were set at 25ºC. The plates were periodically observed 
once in a week for 3 months. 
 
3.2.10 sPLA2 Assay 
PLA2 enzymatic activity was assayed by commercially available secretory 
PLA2 kit from Cayman Chemicals (Ann Arbor, MI, USA). Wild type and the 
mutant enzymes were diluted in assay buffer (25 mM Tris-HCl, pH 7.5 
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containing 10 mM CaCl2, 100 mM KCl and 0.3 mM Triton X-100) prior to 
assaying. 10 µl of sample is added in a 96 well clear bottom plate (Corning, 
NY, USA) followed by 10 µl 10 mM DTNB. The reaction is initiated by 
addition of 200 µl substrate solution (1.66 mM Diheptanoyl thio-PC). 
Absorbance is read at 405 nm using a Tecan Sunrise plate reader (Tecan, 
Maennedorf, Switzerland) at an interval of 30 sec for 15 min. Activity is 













3.3.1 Rational design of 1st generation mutants 
In the prokaryotic PLA2, since the first two N-terminal helices are situated 
away from the C-terminal three-helix catalytic core, it was predicted to not 
take part in the catalysis. So our first set of mutants designed to generate 
smaller scaffold was to remove the helices from the N-terminus of the 
molecule. Based on the available x-ray crystal structure, our first generation of 
mutants comprised of ∆ Helix 1; first helix removed, and ∆ Helix 1 & 2; first 
and second helix removed (Figure 3.1).  
 
Figure 3.1 Rational design of 1st generation mutants 







3.3.2 PLA2 minimization by chemical cleavage 
As discussed in section 2.3.3.1, regarding the basis of point mutations and 
optimization of point mutant expression, our first strategy for generation of 
smaller scaffold was to express and purify the full length molecule with 
incorporated point mutations (to assist chemical cleavage), followed by its 
cleavage by specific chemicals. To generate ∆ Helix 1, chemical cleavage 
point was introduced after the first helix with the mutation A22G. This led to 
the introduction of cleavage point by hydroxylamine (N-G). In the similar way 
to generate ∆ Helix 1 & 2, cyanogen bromide cleavage point was introduced 
by two round of mutagenesis A35M and M92L. The sequences of the two 
mutants aligned with the wild type sequence are shown in the Figure 3.2. 
 
Figure 3.2 Mutations introduced to assist chemical cleavage 
Top row; wild type sequence. Middle row; ∆ Helix 1 sequence, point mutation 
A22G inserted to facilitate cleavage by hydroxylamine. Bottom row; ∆ Helix 1 
& 2 sequence, point mutations A35M and M92L inserted to facilitate cleavage 
by cyanogen bromide at 35
th






Wild Type:      APADKPQVLASFTQTSASSQNAWLAANRNQSAWAAYEFDW 
∆ Helix 1:        APADKPQVLASFTQTSASSQNGWLAANRNQSAWAAYEFDW 
∆ Helix 1 & 2: APADKPQVLASFTQTSASSQNAWLAANRNQSAWAMYEFDW 
 
Wild Type:      STDLCTQAPDNPFGFPFNTACARHDFGYRNYKAAGSFDANKR 
∆ Helix 1:        STDLCTQAPDNPFGFPFNTACARHDFGYRNYKAAGSFDANKR 
∆ Helix 1 & 2: STDLCTQAPDNPFGFPFNTACARHDFGYRNYKAAGSFDANKR 
 
Wild Type:      SIDSAFYEDMKRVCTGYTGEKNTACNSTAWTYYQAVKIFG 
∆ Helix 1:        SIDSAFYEDMKRVCTGYTGEKNTACNSTAWTYYQAVKIFG 
∆ Helix 1 & 2: SIDSAFYEDLKRVCTGYTGEKNTACNSTAWTYYQAVKIFG 
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3.3.2.1 Expression and purification of wild type PLA2 
The wild type PLA2 was expressed and purified as a control. The enzyme was 
expressed by the optimized protocol described earlier. After expression, the 
culture media was analyzed by SDS PAGE to access for expression of the 
protein in the culture supernatant (Figure 3.3 a). After confirmation of 
expression, the culture supernatant was salted out to 50% saturation by 
ammonium sulphate. The precipitate was purified by size exclusion 
chromatography by loading onto GE Superdex 75 prep column. The protein 
peak indicated by an arrow (Figure 3.3 b) was analyzed by ESI LCMS to 
confirm the fully oxidized mass (Figure 3.3 c). After confirmation of the mass, 




Figure 3.3 Expression and purification of wild type PLA2 
A. SDS PAGE analysis showing extracellular expression of wild type PLA2.  
M- Marker, U- Uninduced whole cell lysate, B- Culture broth, C- Induced 
whole cell lysate. 
B. Purification of wild type PLA2 by size exclusion chromatography using 
superdex 75 prep column. 
C. Mass of the protein determined by ESI Ion-Trap mass spectrometry. 
 
 
3.3.2.2 Expression and purification of mutant A22G 
Expression and purification protocol followed for the mutant A22G was 
exactly the same as that of the wild type. The SDS PAGE analysis, gel 
filtration chromatogram and the mass spectrum of the purified protein is 
shown in Figure 3.4. 





















































































































































Figure 3.4 Expression and purification of mutant A22G 
A. SDS PAGE analysis showing extracellular expression of mutant A22G.  
M- Marker, U- Uninduced whole cell lysate, B- Culture broth, C- Induced 
whole cell lysate. 
B. Purification of wild type PLA2 by size exclusion chromatography using 
superdex 75 prep column. 
C. Mass of the protein determined by ESI Ion-Trap mass spectrometry. 
 
 
3.3.2.3 Expression and purification of mutant A35M-M92L 
Expression and purification protocol followed for the mutant A35M-M92L 
was exactly the same as that of the wild type. The SDS PAGE analysis, gel 
filtration chromatogram and the mass spectrum of the purified protein is 
shown in Figure 3.5. 





















































































































































Figure 3.5 Expression and purification of mutant A35M-M92L 
A. SDS PAGE analysis showing extracellular expression of mutant A35M-
M92L.  
M- Marker, U- Uninduced whole cell lysate, B- Culture broth, C- Induced 
whole cell lysate. 
B. Purification of wild type PLA2 by size exclusion chromatography using 
superdex 75 prep column. 
C. Mass of the protein determined by ESI Ion-Trap mass spectrometry. 
 
 
3.3.2.4 Cleavage of mutant A22G with hydroxylamine 
To generate the mutant ∆ Helix 1, hydroxylamine cleavage was performed on 
the mutant A22G. The lyophilized protein was dissolved in hydroxylamine 
cleavage buffer (2 M hydroxylamine, 2 M urea, 0.5 mM EDTA, 200 mM tris-
HCl pH 9) at a concentration of 0.2 mg/ml. The cleavage reaction was 



















































































































































incubated at 45°C and monitored until 20 h by withdrawing aliquots at 0, 4, 8, 
20 h. The extent of cleavage was assessed from the SDS PAGE analysis 
(Figure 3.6 a). The SDS PAGE analysis shows that the maximum amount of 
cleavage product formed at 4 h after which the cleaved protein band 
disintegrated probably due to degradation at higher temperature for longer 
incubation time. Therefore the cleavage reaction was stopped at 4 h followed 
by separation by reversed phase chromatography (Figure 3.6 b). As depicted 
from the chromatogram, the peak was not able to resolve completely even with 
a very shallow gradient. The mass spectrum shows the exact molecular weight 
of the cleaved ∆ Helix 1, with contaminating full length uncleaved enzyme 
(Figure 3.6 c). Since the uncleaved full length protein was not removed 





Figure 3.6 Cleavage of mutant A22G with hydroxylamine 
A. SDS PAGE analysis showing time course of hydroxylamine cleavage 
reaction. The extent of cleavage  
with respect to incubation time (0 h, 4 h, 8 h, 20 h run on lanes 3 through 6) 
compared with uncleaved sample (lane2). 
B. Purification of cleaved products by reversed phase chromatography using 
Jupiter  C-18 analytical column.  
The cleaved product was not resolved completely from the uncleaved, full 
length molecule. 
C. Mass of the truncated protein determined by ESI Ion-Trap mass 
spectrometry. 
 
3.3.2.5 Cleavage of mutant A35M-M92L with cyanogen bromide 
To generate the mutant ∆ Helix 1 & 2, cyanogen bromide cleavage was 
performed on the mutant A35M-M92L. Lyopholized protein was dissolved in 
CNBr cleavage solution (300 times molar excess of CNBr over met residues, 
70% TFA) to a final concentration of 1 mg/ml protein. The reaction was 









































































































































cleavage mixture was lyophilized followed by purification by reversed phase 
chromatography. Although the CNBr cleavage reaction is >90% efficient, the 
sticky nature of the uncleaved full length mutant made it to elute over a broad 
range at the same %B on the gradient where the cleaved mutant eluted. The 
peak of the mutant ∆ Helix 1 & 2 had carryover of the uncleaved full length 
protein which interfered with the assay giving us false positive results. The 
reversed phase chromatogram and the mass spectrum of the cleaved mutant ∆ 
Helix 1 & 2 is shown in Figure 3.7 a and b. 
 
Figure 3.7 Cleavage of mutant A35M-M92L with cyanogen bromide 
A. Purification of cleaved products by reversed phase chromatography using 
Jupiter  C-18 analytical column. 




The problems faced using the strategy of chemical cleavage, was partly due to 
the sticky behavior of the prokaryotic PLA2 to reversed phase matrix and 
partly due to the nature of chemical cleavage, which led to side reactions 























































































































next strategy was to clone and express the first generation mutants with 
solubilization tags. 
3.3.3 Expression of minimized mutants ∆ Helix 1 and ∆ Helix 1 & 2 
with solubilization tags 
The mutants were cloned and expressed with commonly used solubilization 
tags such as the thioredoxin, GST and MBP as fusion which would be later 
cleaved to generate the mutants. 
3.3.3.1 Expression of wild type PLA2, ∆ Helix 1 and ∆ Helix 1 & 2 with 
thioredoxin (Trx) tag in pET 32a 
The first generation mutants along with the wild type enzyme was cloned in 
pET 32a and expressed. The wild type expressed as soluble protein but the 
mutants were formed as inclusion body protein (Figure 3.8 a and b). Therefore 





Figure 3.8 Expression of wild type PLA2, ∆ Helix 1 and ∆ Helix 1 & 2 
with thioredoxin (trx) tag in pET 32a 
SDS PAGE analysis showing expression of wild type and mutant PLA2 with 
trx tag.  
M- Marker, U- Uninduced whole cell lysate, h- hours after induction, S- 
soluble fraction of whole cell lysate, P- pellet containing insoluble fraction of 
whole cell lysate . 
A. Wild type with trx tag expressed as soluble protein. 
B. ∆ Helix 1 and ∆ Helix 1 & 2 with trx tag expressed as insoluble protein. 
 
 
3.3.3.2 Expression of wild type PLA2, ∆ Helix 1 and ∆ Helix 1 & 2 with 
glutathione S-transferase (GST) tag 
After the failure of expression of mutants in soluble form with Trx tag, the 
first generation mutants along with the wild type enzyme was cloned as a GST 
fusion and expressed. The wild type expressed as soluble fusion protein, 
bound and cleaved on column to yield active enzyme but, ∆ Helix 1 was 
expressed as insoluble fusion protein and ∆ Helix 1 & 2 although expressed as 
soluble fusion, was unable to bind to the glutathione sepharose matrix (Figure 
3.9 a, b and c). Therefore we further moved on to check the expression of the 
mutants with a much larger tag, i.e, MBP. 
M       UN        4 h        8 h      16 h      20 h 
37 kDa 
25 kDa 
   M      UN    20 h     S         P                UN     20 h      S        P 
Wild type ∆ Helix 1 
24 kDa 





Figure 3.9 Expression of wild type PLA2, ∆ Helix 1 and ∆ Helix 1 & 2 
with glutathione S-transferase (GST) tag 
SDS PAGE analysis showing expression of wild type and mutant PLA2 with 
GST tag for increasing solubility, 6x His tag (in pLIC-GST) used in A and B 
for affinity purification.   
M- Marker, U- Uninduced whole cell lysate, S- soluble fraction of whole cell 
lysate, P- pellet containing insoluble fraction of whole cell lysate, FT- flow 
thorugh, W- wash, E-eluate, BB- bound beads. 
A. Wild type with GST tag (pLIC-GST) expressed as soluble protein in very 
low amount, followed by Ni-NTA chromatography and on-column TEV 
cleavage. 
B. ∆ Helix 1 with GST tag (pLIC-GST) expressed as insoluble protein (major 
part), followed by Ni-NTA chromatography and on-column TEV cleavage. 
C. ∆ Helix 1 & 2 with GST tag (pGEX-4T1) expressed as soluble protein 
(although a part was insoluble), followed by Glutathione Sepharose  
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3.3.3.3 Expression of wild type PLA2, ∆ Helix 1 and ∆ Helix 1 & 2 with 
maltose binding protein (MBP) tag 
After encountering problems with expression of mutants in soluble form with 
Trx and GST tag, we gave a final try on a much larger MPB tag. The first 
generation mutants along with the wild type enzyme was cloned as a MBP 
fusion and expressed. The wild type expressed as soluble fusion protein, 
bound and cleaved on column to yield active enzyme. On the other hand, ∆ 
Helix 1 and ∆ Helix 1 & 2 although expressed as soluble fusion, bound to 
amylose matrix, but after cleavage of the tag was not eluted out of the column 




Figure 3.10 Expression of wild type PLA2, ∆ Helix 1 and ∆ Helix 1 & 2 
with maltose binding protein (MBP) tag 
SDS PAGE analysis showing expression of wild type and mutant PLA2 with 
MBP tag for increasing solubility and 6x His tag for affinity purification.  
M- Marker, U- Uninduced whole cell lysate, S- soluble fraction of whole cell 
lysate, P- pellet containing insoluble fraction of whole cell lysate, FT- flow 
thorugh, W- wash, E-eluate, BB- bound beads. 
A. Wild type with MBP tag (pLIC-MBP) expressed as soluble protein, 
followed by Ni-NTA chromatography and on-column TEV cleavage. 
B. ∆ Helix 1 with MBP tag (pLIC-MBP) expressed as soluble protein 
(although a part was insoluble), followed by Ni-NTA chromatography and on-
column TEV cleavage. 
C. ∆ Helix 1 & 2 with MBP tag (pLIC-MBP) expressed as soluble protein 




Expression with different solubilization tags were able to produce the wild 
type enzyme in the soluble form but the first generation mutants were mostly 
expressed as inclusion body protein. Therefore we went forward to refold the 
wild type and the mutants from the inclusion body. 
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3.3.4 Expression of wild type, ∆ Helix 1 and ∆ Helix 1 & 2 for 
refolding from inclusion body 
Although refolding of proteins to their active forms from inclusion body is a 
relatively complex process, there are advantages in refolding proteins from 
inclusion body. A large amount of protein is produced as inclusion body which 
can be purified by established protocols. Inclusion body proteins due to their 
misfolded nature, are not susceptible to protease cleavage during the course of 
purification and if refolding process is optimized well, we can get a good final 
refolded yield.  
Since the wild type and the mutants are relatively simple in their structure with 
two disulphide bonds, we first wanted to refold them on column by binding 
the His tagged protein to the Ni-NTA resin, without reducing their disulphide 
bonds. 
3.3.4.1 Expression and on-column refolding of wild type PLA2 and ∆ 
Helix 1 & 2 with 6x His tag 
Wild type PLA2 and ∆ Helix 1 & 2 was cloned in to pET M (modified pET 
vector) for expression with 6x His tag. These His tagged proteins were 
expressed as inclusion body (Figure 3.11 a and b), denatured in buffer 
containing 8 M urea. Following denaturation, the protein solution was bound 
to Ni-NTA resin and gradually re-natured by washing the resin with buffers 
containing decreasing amounts of urea. Finally after wash with buffer 
containing 2 M urea, the proteins were eluted with native condition buffer 
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containing 250 mM imidazole. The wild type protein was able to refold and 
elute from the column and was fully functional (Figure 3.11 a) but the mutant 
was not eluted and found to be precipitated on the resin (Figure 3.11 b). 
 
Figure 3.11 Expression and on-column refolding of wild type PLA2 and ∆ 
Helix 1 & 2 with 6x His tag 
SDS PAGE analysis showing expression and on-column refolding of wild type 
and ∆ Helix 1 & 2 with 6x His tag .  
M- Marker, WCL-induced whole cell lysate, S- soluble fraction of whole cell 
lysate, P- pellet containing insoluble fraction of whole cell lysate, FT- flow 
thorugh, W- wash, E-eluate, BB- bound beads, 8-2M-Urea molar 
concentration in wash buffer. 
A. Wild type with 6x his tag denatured in 8 M urea buffer followed by Ni-
NTA chromatography and on-column refolding  
by gradual reduction in the urea concentration in wash buffer. The wild type 
enzyme was successfully refolded on-column  
and eluted with native condition buffer containing imidazole. The eluted 
enzyme showed activity comparable to reported value. 
B. ∆ Helix 1 & 2 with 6x his tag denatured and refolded as explained above, 
but no protein was eluted in the native condition buffer  
and most of the protein was found bound to the beads, suggesting protein 
precipitation during the course of decrease in the  
urea concentration in the wash buffer. Hence the ∆ Helix 1 & 2 was unable to 
refold on-column as seen for the wild type. 
 
 
Since the mutant was not able to re-fold to soluble form using this technique 
of on-column refolding, we finally resorted to refolding the wild type and the 
M  WCL  S     P    FT  8M  6M  4M 2M  E1 E2 BB  M        S         P        FT      8M    6M      4M     2M      E1      E2  
Wild type ∆ Helix 1 & 2 
A B 




mutants by denaturation, reduction followed by refolding using a redox 
couple. 
3.3.4.2 Expression, refolding and purification of wild type PLA2 
For refolding using a redox couple, first the expressed inclusion body (Figure 
3.12 a) was washed several times with lysis buffer containing a detergent to 
get rid of other contaminating membrane fractions and cellular debris. This 
semi-purified inclusion body (Figure 3.12 b) is completely denatured and 
reduced. The complete reduction of the protein is assessed by analyzing the 
reduced protein by ESI LCMS (Figure 3.12 d). The reducing agent is removed 
by extensive dialysis followed by refolding in a redox buffer. The refolding is 
performed by dilution technique as explained earlier. The refolding solution is 
purified by reversed phase chromatography (Figure 3.12 c) and finally the 
purified refolded protein is analyzed by ESI MS to confirm the complete 




Figure 3.12 Expression, refolding and purification of wild type PLA2 
A and B. SDS PAGE analysis showing expression and inclusion body 
preparation, respectively.  
M- Marker, U- Uninduced whole cell lysate, IN- Induced whole cell lysate, 
Sol- Fraction containing soluble proteins, Insol- Fraction containing insoluble 
proteins, IB- Inclusion body after washing with 2% sodium deoxycholate. 
C. Purification of refolded wild type PLA2 by reversed phase chromatography 
using Jupiter C-18 column. 
D and E. Mass of the reduced and refolded proteins, respectively, determined 
by ESI Ion-Trap mass spectrometry, showing the reduction of four Daltons as 
a result of two disulphide bond formation. 
 
 
3.3.4.3 Expression, refolding and purification of ∆ Helix 1 
The expression, refolding and purification method followed was the same as 
for the wild type. The expression, inclusion body preparation, purification 
chromatogram and mass spectrum of reduced and refolded protein is shown in 
Figure 3.13. 
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15348.19 ± 0.86 Da 





Figure 3.13 Expression, refolding and purification of ∆ Helix 1 
A and B. SDS PAGE analysis showing expression and inclusion body 
preparation, respectively.  
M- Marker, U- Uninduced whole cell lysate, IN- Induced whole cell lysate, 
Sol- Fraction containing soluble proteins, Insol- Fraction containing insoluble 
proteins, IB- Inclusion body after washing with 2% sodium deoxycholate. 
C. Purification of refolded wild type PLA2 by reversed phase chromatography 
using Jupiter C-18 column. 
D and E. Mass of the reduced and refolded proteins, respectively, determined 
by ESI Ion-Trap mass spectrometry, showing the reduction of four Daltons as 
a result of two disulphide bond formation. 
 
 
3.3.4.4 Expression, refolding and purification of ∆ Helix 1 & 2 
The expression, refolding and purification method followed was the same as 
for the wild type. The expression, inclusion body preparation, purification 
chromatogram and mass spectrum of reduced and refolded protein is shown in 
Figure 3.14. 
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Figure 3.14 Expression, refolding and purification of ∆ Helix 1 & 2 
A and B. SDS PAGE analysis showing expression and inclusion body 
preparation, respectively.  
M- Marker, U- Uninduced whole cell lysate, IN- Induced whole cell lysate, 
Sol- Fraction containing soluble proteins, Insol- Fraction containing insoluble 
proteins, IB- Inclusion body after washing with 2% sodium deoxycholate. 
C. Purification of refolded wild type PLA2 by reversed phase chromatography 
using Jupiter C-18 column. 
D and E. Mass of the reduced and refolded proteins, respectively, determined 
by ESI Ion-Trap mass spectrometry, showing the reduction of four Daltons as 
a result of two disulphide bond formation. 
 
 
3.3.5 Circular dichroism spectroscopy of refolded wild type and 
mutants 
After refolding the wild type and the mutants and assessing their complete 
oxidation of the cysteines, the next step was to check their secondary structure 
by CD spectroscopy. The refolded protein solutions were made and CD 
spectra (Far-UV, 260-190 nm) were recorded using a spectropolarimeter in 
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triplicates and finally the base line was substracted from the average. From the 
spectra generated for the wild type and the mutants, the minima at 208 and 222 
nm confirms the presence of alpha helical content (Figure 3.15). 
 
Figure 3.15 Circular dichroism spectroscopy of refolded wild type and 
mutants 
A. Wild type  B. ∆ Helix 1  C. ∆ Helix 1 & 2. Minima at 208nm and 222nm 
show the presence of alpha helical content in the proteins. 
 
 
3.3.6 Disulphide linkage determination of first generation mutants 
Refolding proteins using a redox couple after complete reduction of the 
disulphides would form new disulphide bonds in thermodynamically most 
preferred combination where the free energy is the minimum. Therefore after 
knowing the presence of alpha helical content in the mutants we wanted to 






















































































Disulphide linkage was determined by trypsin digest of the mutants followed 
by ESI LCMS. The fragments detected form the total ion chromatogram was 
matched with the theoretical fragments. By tallying the exact mass of the 
fragment from the mass spectrum and the expected theoretical mass, the 
disulphide linkage pattern for the mutants were deduced. 
3.3.6.1 Disulphide linkage determination of ∆ Helix 1 
From the total ion chromatogram, the peaks corresponding to the theoretical 
mass of the peptides containing the disulphide were identified (Figure 3.16 a, 
b and c). These fragments were matched with the theoretical fragments 
containing the disulfide bonds shown in Table 3.1. With these information the 
final disulphide linkage was determined to be in 1-2 3-4 pattern, which is the 




Figure 3.16 Disulphide bond determination of ∆ Helix 1 
A. Total ion chromatogram of LC-MS run of tryptic digest of ∆ Helix 1 
B. Mass of peptide 79-87 and 88-103, linked by the second disulphide 
bond. 



































































































































2775.7   0.3 Da 











































Figure 3.17 Disulphide linkage assignment of ∆ Helix 1 
A. Disulphide bonding pattern of ∆ Helix 1, as deduced from the above 
peptide masses, showing wild type-like cysteine pairing. 












1-12 ASSQNAWLAANR 1288.3853   1288.2 
13-47 NQSAWAAYEFDWSTDLCTQA 
PDNPFGFPFNTACAR 
3943.2492 3941.25 3940.9 
48-53 HDFGYR 793.8370   793.6 
54-56 NYK 423.4692     
57-65 AAGSFDANK 879.9249   879.7 
66-67 SR 261.2810     
68-77 IDSAFYEDMK 1218.3437 1374.5/1218.4 
78-78 R 174.2028 
79-87 VCTGYTGEK 957.0663 2776.05 2775.7 
88-103 NTACNSTAWTYYQAVK 1820.9942 












3.3.6.2 Disulphide linkage determination of ∆ Helix 1 & 2 
From the total ion chromatogram, the peaks corresponding to the theoretical 
mass of the peptides containing the disulphide were identified (Figure 3.18 a, 
b and c). These fragments were matched with the theoretical fragments 
containing the disulfide bonds shown in Table 3.2. With these information the 
final disulphide linkage was determined to be in 1-2 3-4 pattern, which is the 
same found in the wild type enzyme (Figure 3.19 a and b). 
 
Figure 3.18 Disulphide bond determination of ∆ Helix 1 & 2 
A. Total ion chromatogram of LC-MS run of tryptic digest of ∆ Helix 1 
&2 
B. Mass of peptide 55-63 and 64-79, linked by the second disulphide 
bond. 
















































































































































































Table 3.2 Theoretical and experimental masses of tryptic fragments of ∆ 




Figure 3.19 Disulphide linkage assignment of ∆ Helix 1 & 2 
A. Disulphide bonding pattern of ∆ Helix 1 & 2, as deduced from the 
above peptide masses, showing wild type-like cysteine pairing. 
B. The peptides with disulphide bonds. 
 
 
3.3.7 Assay for PLA2 activity for refolded wild type, ∆ Helix 1 and 
∆ Helix 1 & 2 
Assay for enzymatic activity of the wild type and the first generation mutants 
were performed using commercially available assay kit from Cayman 








1-23 STDLCTQAPDNPFGFPFNTACAR 2473.7170 2471.71 2471.7 
24-29 HDFGYR 793.8370   793.7 
30-32 NYK 423.4692     
33-41 AAGSFDANK 879.9249   879.7 
42-43 SR 261.2810     
44-53 IDSAFYEDMK 1218.3437   1374.8/1218.4 
54-54 R 174.2028   
55-63 VCTGYTGEK 957.0663 2776.05 2776.2 
64-79 NTACNSTAWTYYQAVK 1820.9942 












chemicals. The assay methodology is described earlier. From the assay, 
although the wild type enzyme showed enzymatic activity as reported before, 
the first generation mutants failed to show any detectable activity up to a 
molar concentration of 400 folds higher than the wild type enzyme (Figure 
3.20).  
 
Figure 3.20 Assay for PLA2 activity for refolded wild type, ∆ Helix 1 and 
∆ Helix 1 & 2 
Although the wild type refolded enzyme was active with specific activity 




3.3.8 Rational design of 2nd generation mutants 
After the 1
st
 generation of mutants failed to show any enzymatic activity, 
despite with correct disulphide linkage and alpha helical content in the 
secondary structure, we wanted to design a 2
nd
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analyzed the structure and looked into the interface between the C-terminal 
three-helix catalytic core and the N-terminal 2-helix domain. After the 
removal of the N-terminal 2-helix domain, the interface would be exposed to 
the polar solvent. Hydrophobic nature of the exposed surface might cause 
distortion to the molecule (Figure 3.21 a), possibly leading to the loss of 
activity due to subtle changes in the geometry of the active site residues. 
Therefore, our first step towards re-engineering the mutant was to neutralize 
the hydrophobic surface of the mutant ∆ Helix 1 & 2 (Figure 3.21 b). The 
exposed surface had two hydrophobic residues, phenylalanine at 66
th
 position 
and tyrosine at 71
st
 position. Therefore we replaced these hydrophobic 
residues to polar residue glutamine. The new generation of mutant was ∆ 




Figure 3.21 Rational design of 2st generation mutants 
A. Residues at interface, hydrophobic residues of mutant ∆ Helix 1 & 2 
highlighted in orange.  
B. Protruding hydrophobic residues at the interface, which are exposed to the 
solvent in mutant ∆ Helix 1 & 2. 
 
 
3.3.8.1 Expression, refolding and purification of ∆ Helix 1 & 2- F66Q-
Y71Q 
The expression, refolding and purification method followed was the same as 
for the wild type. The expression, inclusion body preparation, purification 
chromatogram and mass spectrum of reduced and refolded protein is shown in 
Figure 3.22. 
B 





Figure 3.22 Expression, refolding and purification of 2nd generation 
mutant, ∆ Helix 1 & 2- F66Q-Y71Q 
A and B. SDS PAGE analysis showing expression and inclusion body 
preparation, respectively.  
M- Marker, U- Uninduced whole cell lysate, IN- Induced whole cell lysate, 
Sol- Fraction containing soluble proteins, Insol- Fraction containing insoluble 
proteins, IB- Inclusion body after washing with 2% sodium deoxycholate. 
C. Purification of refolded wild type PLA2 by reversed phase chromatography 
using Jupiter C-18 column. 
D and E. Mass of the reduced and refolded proteins, respectively, determined 
by ESI Ion-Trap mass spectrometry, showing the reduction of four Daltons as 
a result of two disulphide bond formation. 
 
. 
3.3.8.2 Circular dichroism spectroscopy of refolded wild type and 
mutants 
After refolding the 2
nd
 generation mutant and assessing the complete oxidation 
of the cysteines, the next step was to check its secondary structure by CD 
spectroscopy. CD spectra (Far-UV, 260-190 nm) were recorded using a 
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9118.98   0.84 Da 
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spectropolarimeter in triplicates and finally the base line was substracted from 
the average. From the spectra generated for the 2
nd
 generation mutant, the 
minima at 208 and 222 nm confirms the presence of alpha helical content 
(Figure 3.23). 
 
Figure 3.23 Circular dichroism spectroscopy for ∆ Helix 1 & 2- F66Q-
Y71Q 
Minima at 208nm and 222nm show the presence of alpha helical content in the 
mutant ∆ Helix 1 & 2- F66Q-Y71Q. 
 
 
3.3.8.3 Disulphide linkage determination of ∆ Helix 1 & 2- F66Q-Y71Q 
From the total ion chromatogram, the peaks corresponding to the theoretical 
mass of the peptides containing the disulphide were identified (Figure 3.24 a, 
b and c). These fragments were matched with the theoretical fragments 
containing the disulfide bonds shown in Table 3.3. With these information the 
final disulphide linkage was determined to be in 1-2 3-4 pattern, which is the 






























Figure 3.24 Disulphide bond determination for ∆ Helix 1 & 2- F66Q-
Y71Q 
A. Total ion chromatogram of LC-MS run of tryptic digest of ∆ Helix 1 & 
2- F66Q-Y71Q 
B. Mass of peptide 55-63 and 64-79, linked by the second disulphide 
bond. 





























































































































2776.07   0.51 Da 

















Table 3.3 Theoretical and experimental masses of tryptic fragments of ∆ 




Figure 3.25 Disulphide linkage assignment of ∆ Helix 1 & 2- F66Q-Y71Q 
A. Disulphide bonding pattern of ∆ Helix 1 & 2- F66Q-Y71Q, as deduced 
from the above peptide masses, showing wild type-like cysteine 
pairing. 
B. The peptides with disulphide bonds. 
 
 
3.3.8.4 Assay for PLA2 activity for refolded ∆ Helix 1 & 2- F66Q-Y71Q 
Assay for enzymatic activity of the 2
nd
 generation mutant was performed using 
commercially available assay kit from Cayman chemicals. The assay 








1-23 STDLCTQAPDNPFGFPFNTACAR 2473.7170 2471.71 2471.9 
24-29 HDQGYR 774.7911     
30-32 NQK 388.4239     
33-41 AAGSFDANK 879.9249   879.7 
42-43 SR 261.2810     
44-53 IDSAFYEDMK 1218.3437 1374.54 1374.5 
54-54 R 174.2028 
55-63 VCTGYTGEK 957.0663 2776.05 2776.0 
64-79 NTACNSTAWTYYQAVK 1820.9942 












methodology is described earlier. From the assay, although the wild type 
enzyme showed enzymatic activity as reported before, the 2
nd
 generation 
mutant failed to show any detectable activity up to a molar concentration of 
400 folds higher than the wild type enzyme (Figure 3.26).  
 
Figure 3.26 Assay for PLA2 activity for refolded ∆ Helix 1 & 2- F66Q-
Y71Q 
Although the wild type refolded enzyme was active with specific activity 
comparable with reported values, the 2
nd
 generation mutant failed to show 
detectable enzymatic activity. 
 
 
3.3.9 Crystallization of refolded ∆ Helix 1 & 2  
Crystallization conditions for ∆Helix 1 & 2 were screened with different 
crystallization screens (Crystal Screen 1, Crystal Screen 2, Index, Wizard 1, 
Wizard 2, Wizard 3, Wizard 4, JCSG 1, JCSG 2) using a sitting-drop vapour-
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due to its poor solubility in any buffered solution after reversed phase 
purification. The drops were set at a concentration of 10 and 20 mg/ml by 
Mosquito crystallization robot. The plates were set at 25ºC. After 24 hours of 
setting the drops, heavy precipitation was seen in more than 80% of the 
conditions. The remaining clear drops were monitored every week upto 3 















In this chapter we were able to design and test the function of two generations 
of mini prokaryotic PLA2 mutants. Although the design of the mini mutants, 
were based on conserved topology of catalytic core and active site geometry in 
secretory PLA2s (Hariprasad et al., 2013; Nevalainen and Cardoso, 2012), 
rational design was chosen as our preferred method as the three dimensional 
structure of the prokaryotic PLA2 was available. The rational approach lets us 
design mutants based on the existing information of the structure or fold of the 
protein. On the other hand computational methods, although used in some 
studies to engineer proteins, have met with limited success (Bolon and Mayo, 
2001; Korkegian et al., 2005; Stevens et al., 2006). Moreover the huge number 
of possible mutants generated by computational algorithms would make it a 
mammoth task to produce and test them. 
The prokaryotic PLA2 being one of the smallest and structurally simplest 
among secretory PLA2 enzymes, with just two disulphides and N-terminal 
protruding 2-Helix bundle, provides a model which seems to be more 
amenable to minimization, deletion mutations and more importantly 
disulphide bond formation and its easy assessment. The conserved nature of 
the PLA2 catalytic core and active site geometry evoked initial questions that, 
can the conserved catalytic core can be designed as a functional mini PLA2 
scaffold? A small active PLA2 scaffold would not only test our understanding 
of protein folding and function, but also provide a starting point for the further 
design of other biologics in a modular fashion. 
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To minimize the prokaryotic PLA2, a few approaches have been taken. The 
first approach considered was chemical cleavage of the full length protein 
incorporating specific mutations to aid the cleavage. Although the efficiency 
of chemical cleavage depends on the nature of the cleavage (chemicals used 
for cleavage; hydroxylamine ~30% efficiency, CNBr ~90% efficiency) 
(Crimmins et al., 2005) and the strategic optimization with the protein, the 
prokaryotic PLA2 harboring the mutations seemed to cleave with cleavage 
efficiency reported earlier (Andreev et al., 2010; Milner et al., 1996). However 
the approach was not reliable in our case due to the sticky nature of the protein 
on the reversed phase matrix, leading to co-elution and contamination of the 
protein fragment peak of interest with the full length enzyme. If complete 
separation of the fragment of interest could not be achieved, it would give 
false positive results in the downstream functional assessment.  
Therefore our next strategy was to express the minimized mutants with 
solubilization tags, which would eliminate any possibility of contamination 
with the full length, wild type enzyme. The wild type and the first generation 
mutants (∆ Helix 1, ∆ Helix 1 & 2) were expressed with commonly used 
solubilization tags such as thioredoxin, GST and MBP. Although in all the 
cases the wild-type fusion protein was produced in soluble form, the mutants 
either expressed as inclusion body proteins or precipitated after removing the 
tag (observed in case of MBP fusion (section 3.3.3.3). Therefore finally we 
resorted to refolding the mutants from the inclusion body. Initial refolding 
experiments were performed by denaturing followed by re-naturing the protein 
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on column, without reducing the disulphides. But we had success only with 
the wild type as the mutant was precipitated on column. These sets of 
experiments on expression of the mutants lacking either the first or the first 2-
helices indicated that these two helices were important for the folding of the 
molecule hence aiding its production in soluble form. This was consistent with 
the observation of the expression of Helix short mutant with pelB signal 
(section 2.3.2.4), where it having the N-terminal two helices intact was able to 
express in soluble form and get transported into the periplasm. 
The final and the fool-proof way of producing the mutants were to denature, 
reduce and refold using a redox couple followed by assessment of the 
disulphide linkages. Refolding using a redox couple shuffles the disulphide 
bonds till the molecule reaches a thermodynamically stable energy state 
(Vallejo and Rinas, 2004). This leads to the formation of majority of the 
refolded proteins with identical disulphide linkage pattern. After the 
purification of the refolded protein, it was evaluated for correct folding by 
analysis of its refolded mass and determination of its disulphide linkage 
pattern. Reduction in the same number of Daltons as the number of cysteines 
confirmed its complete oxidation and the tryptic fragments of the mutants 
corresponding to its theoretical mass confirmed its correct dilulphide pairing 
compared to the wild type enzyme. 
As the first generations of the mutants were non-functional despite its correct 
disulphide pairing and alpha helical secondary structure, the second generation 
of the mutant was designed by neutralizing the hydrophobic surface of ∆ Helix 
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1 & 2. Two hydrophobic residues protruding to the solvent was replaced with 
polar residue glutamine. The designed second generation mutant, ∆ Helix 1 & 
2- F66Q-Y71Q, following refolding and assessment of its disulphides linkages 
was also found to be inactive. To probe into the exact structural changes which 
led to the functional inactivation of the mutants, the three dimension structural 
information was needed. Therefore the smallest mutant ∆ Helix 1 & 2 was set 
for crystallization. But due to the solubility issues, >80% of the drops 
precipitated. The reduction in solubility of the protein was observed after 
purification by reversed phase chromatography, therefore alternate ways of 
purifying in milder condition (using only aqueous buffers) need to be devised 
followed by screening for crystallization. 
The functional inactivation of the mutants may be attributed to two reasons. 
First, changes in the geometry of active site residues may lead to loss of 
activity. Second, distortion of the calcium binding loop may render calcium 
coordination faulty, leading to loss of activity. Although the x-ray crystal 
structure can provide us valuable information regarding both the issues, the 
property of the mutants to bind calcium can be assessed to get clues regarding 
orientation of the calcium binding loop. Therefore further work is needed to 
understand the structure of the current generation mutants to design the next 









































CHAPTER  THREE 




















4 CHAPTER FOUR: Conclusions and future 
perspectives 
4.1 Design of an extracellular expression system 
Exploiting one of the most interesting properties of the prokaryotic PLA2 to 
get secreted into the culture medium, we have demonstrated its usefulness as a 
tag in the extracellular production of other target proteins. To test the system, 
the first target protein selected was krait natriuretic peptide (residues 1-34, 
∆Helix KNP), a molecule with relatively small and simpler structure. PLA2-
∆Helix KNP fusion protein was successfully recovered and purified from the 
culture supernatant. Following the tag cleavage and purification, the target 
protein ∆Helix KNP was found to be biologically active. Moreover, the final 
yield of ∆Helix KNP produced using this system was 2.5 folds higher than the 
yield obtained by conventional way of recovering from inclusion body. As 
demonstrated from the above test protein, using this system for producing 
complex disulphide rich proteins would not only help production of soluble 
and correctly folded protein, but also decrease the downstream purification 
steps. Therefore the next protein selected to test the system was denmotoxin, a 
three finger toxin with five disulphides, much larger and complex than ∆Helix 
KNP. Although the denmotoxin-PLA2 fusion was able to express in the 
extracellular medium with the correct oxidized mass, it resisted cleavage by 
both TEV and HRV 3C protease. Further work need to be done in the future to 
troubleshoot the cleavage problem. The resistance to protease may be due to 
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the stearic hindrance caused by the tag and demnotoxin resulting in burying of 
the protease site in the fusion protein. The linker length near the protease 
cleavage site needs to be optimized for the access of the protease and efficient 
tag cleavage. Next we also wanted to identify the minimal segment of the 
PLA2 which could retain the property of extracellular secretion. Although none 
of the truncated mutants were able to secrete into the extracellular medium, ∆ 
Helix 1 & 2 misfolded as inclusion body and Helix short was able to enter the 
periplasmic space. This experiment illustrated the importance of the N-
terminal helices in enhancing the solubility of the molecule. Also the Helix 
short mutant which was small by just eight residues, failed to secrete to the 
extracellular medium and retained in the periplasmic space. From this 
information, the region of the molecule aiding in the interaction with any 
unknown partners of the bacterial secretion systems leading to its secretion can 
be probed. Next the study of the PLA2 point mutants showed the reduction in 
the yield was due to the lack of secretion rather than expression. The point 
mutations led to the misfolding of the molecule, leading to reduced secretion. 
Optimization at lower temperature was able to increase the yield to 
considerable amount.  
Not only do the system needs to be optimized with different linker lengths for 
efficient tag cleavage, it also needs to be tested with proteins with different 
size and with different complexities, number of disulphide bonds. It also needs 
to be tested with proteins which can only be expressed with solubilization tags 
and proteins which have expression problems even with tags. It would also be 
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of interest to understand the mechanism underlying this export process in E. 
coli. 
 
4.2 Design of a mini PLA2 scaffold 
Another interesting property of the prokaryotic PLA2 is its tertiary structure 
and its preservation of the same topologically conserved three helix catalytic 
core and active site geometry. These unique structural properties provided us 
with a model to design a minimized PLA2 scaffold. Although we were able to 
design and produce the minimized PLA2 scaffold which was 30% smaller than 
the wild type, their biological activity was completely lost. The first generation 
involved the design and production of two mutants, ∆ Helix 1 and ∆ Helix 1 & 
2. After the failure of initial trials of minimization with chemical cleavage and 
usage of solubilizaton tags to express the mutants, we refolded the mutants 
using a redox couple. The purified refolded protein was checked for its 
secondary structure and disulphide linkage. After confirming the structural 
details, the assay for activity was conducted, which showed a complete loss of 
activity. The second generation of mutant was designed by reducing the 
hydrophobic surface of the first generation mutant and the final mutant ∆ 
Helix 1 & 2- F66Q-Y71Q was expressed, refolded and assessed for its 
disulphide linkages. This mutant also showed the complete loss of activity. To 
probe into the structural changes that was responsible for the loss of activity, 
the smallest of the first generation mutant ∆ Helix 1 & 2 was set for 
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crystallization. Unfortunately, the crystallization was not successful due to 
heavy precipitation seen in majority of the drops. The reduction in the 
solubility of the protein was due to its purification by revered phase 
chromatography; hence further work is needed in the future to devise 
strategies to purify the mutant using mild purification condition.  
Crystallization of this mutant is an important future work, as crystal structure 
can only give us detailed insights about the mutant and ideas for designing 
next generation of mutants. Since the mutant ∆ Helix 1 & 2 is around 9 kDa, 
Nuclear Magnetic Resonance spectroscopy might be used to determine the 
solution structure. Structural information would give us idea about the changes 
in the active site geometry, which resulted in total activity loss of the mutants. 
Also we need to check if the mutants retain the calcium binding property.  
This could be achieved by Isothermal Titration Calorimetry.  Negative binding 
results would give us an idea about distortion in calcium binding loop, which 
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